FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Alan Partin

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

Physiology

Disease Progression

Co-author Network

Publications

TOP 3
Jeffrey K Mullins; Alan W Partin; Hosne Begum; David Bonekamp; H Ballentine Carter; Jonathan I Epstein; Patricia Landis; Katarzyna J Macura
Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance.
Phillip M Pierorazio; Patrick C Walsh; Alan W Partin; Jonathan I Epstein
Prognostic Gleason grade grouping: data based on the modified Gleason scoring system.
Stacy Loeb; Leonard S Marks; IA Mizrahi; Alan W Partin; William L Roberts; Martin G Sanda; Sanghyuk S Shin; Kevin M Slawin; Lori J Sokoll; Ron H N van Schaik; John T Wei; Chris H Bangma; Dennis L Broyles; Daniel W Chan; Amabelle B Cruz; George G Klee; William J Catalona
Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alan Partin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jeffrey K Mullins; Alan W Partin; Hosne Begum; David Bonekamp; H Ballentine Carter; Jonathan I Epstein; Patricia Landis; Katarzyna J Macura
Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance.
BJU international 2013;111(7):1037-45.
2013: Phillip M Pierorazio; Patrick C Walsh; Alan W Partin; Jonathan I Epstein
Prognostic Gleason grade grouping: data based on the modified Gleason scoring system.
BJU international 2013;111(5):753-60.
2013: Stacy Loeb; Leonard S Marks; IA Mizrahi; Alan W Partin; William L Roberts; Martin G Sanda; Sanghyuk S Shin; Kevin M Slawin; Lori J Sokoll; Ron H N van Schaik; John T Wei; Chris H Bangma; Dennis L Broyles; Daniel W Chan; Amabelle B Cruz; George G Klee; William J Catalona
Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration.
The Journal of urology 2013;189(5):1702-6.
2013: Yun-Sok Ha; Misop Han; Michael Karellas; Jeong Hyun Kim; Wun-Jae Kim; Dong Hyeon Lee; Alan W Partin; Amirali Salmasi; Eric A Singer; Isaac Yi Kim
Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance.
Urology 2013;81(4):831-5.
2013: Elias S Hyams; Jeffrey K Mullins; Alan W Partin; Phillip M Pierorazio; Mohamad E Allaf; Brian R Matlaga
Impact of robotic technique and surgical volume on the cost of radical prostatectomy.
Journal of endourology / Endourological Society 2013;27(3):298-303.
2013: Jens Hansen; Hartwig Huland; Michael Marberger; Leonard S Marks; Peter F A Mulders; Alan W Partin; Karl Pummer; Jack A Schalken; Shahrokh F Shariat; Arnulf Stenzl; Hendrik van Poppel; Jochen Walz; Clement-Claude Abbou; Sascha A Ahyai; Marco Auprich; Alberto Briganti; Alexandre de la Taille; William Ellis; Margit Fisch; Yves Fradet; Markus Graefen; Alexander Haese; fianceeyi chun
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.
European urology 2013;63(2):201-9.
2013: John B Eifler; Jonathan I Epstein; Zhaoyang Feng; Misop Han; Elizabeth B Humphreys; Brian M Lin; Michael T Partin; Bruce J Trock; Patrick C Walsh; Alan W Partin
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011.
BJU international 2013;111(1):22-9.
2012: H Ballentine Carter; Donald S Coffey; William G Nelson; Alan W Partin; Eric A Singer; Bruce J Trock; Robert W Veltri; Patrick C Walsh; Jonathan I Epstein
Gleason score 6 adenocarcinoma: should it be labeled as cancer?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(35):4294-6.
2012: Misop Han; Chunwoo Kim; Hyung-Joo Kim; Jongwon Kim; Brian J Lee; Alan W Partin; Doru Petrisor; Ronald Rodriguez; Mohamad E Allaf; H Ballentine Carter; Doyoung Chang; Bruce J Trock; Yihe Zuo; Dan Stoianovici
Geometric evaluation of systematic transrectal ultrasound guided prostate biopsy.
The Journal of urology 2012;188(6):2404-9.
2012: Heather J Chalfin; Michael Dinizo; Zhaoyong Feng; Elizabeth Humphreys; Alan W Partin; Bruce J Trock; Patrick C Walsh; Misop Han
Impact of surgical margin status on prostate-cancer-specific mortality.
BJU international 2012;110(11):1684-9.
2012: Adam C Reese; Phillip M Pierorazio; Misop Han; Alan W Partin
Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system.
Urology 2012;80(5):1075-9.
2012: Jeffrey J Tosoian; Bruce J Trock; Robert W Veltri; H Ballentine Carter; Debra J Elliot; Jonathan I Epstein; Zhaoyong Feng; Sumit Isharwal; Patricia Landis; Stacy Loeb; Alan W Partin; Lori J Sokoll
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.
The Journal of urology 2012;188(4):1131-6.
2012: Paul J Dluzniewski; Charles G Drake; MARGARET D FALLIN; Helen L Fedor; Misop Han; William B Isaacs; Alan W Partin; Ming-Hsien Wang; Jianfeng Xu; Siqun Lilly Zheng; Angelo M DeMarzo; Elizabeth A Platz
Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2012;21(10):1774-82.
2012: Phillip M Pierorazio; Ashley E Ross; Patrick C Walsh; Jonathan I Epstein; Misop Han; Brian M Lin; Alan W Partin; Christian P Pavlovich; Edward M Schaeffer
Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.
BJU international 2012;110(8):1122-8.
2012: John Bernard Eifler; Elizabeth B Humphreys; Alan W Partin; Bruce J Trock; Marilyn Agro; Misop Han
Causes of death after radical prostatectomy at a large tertiary center.
The Journal of urology 2012;188(3):798-801.
2012: Eli Rosenbaum; David Sidransky; Marianna Zahurak; Leonel Maldonado; Leslie A Mangold; Alan W Partin; Shahnaz Begum; Mariana Brait; Mario A Eisenberger; Jonathan I Epstein; Mohammad Hoque
AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy.
The Prostate 2012;72(10):1133-9.
2012: Bruce J Trock; Songbai Wang; Bhargavi Raghavan; Joseph W Bigley; Michelle J Brotzman; Jonathan I Epstein; J Stephen Jones; Eric A Klein; Leslie A Mangold; Theresa McAskill; David McLeod; Jyoti Mehrotra; Alan W Partin
Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies.
BJU international 2012;110(1):56-62.
2012: Naoki Terada; David B Yeater; Yu Zeng; PRAKASH KULKARNI; Leslie A Mangold; Steven M Mooney; Alan W Partin; Takumi Shiraishi; Robert H Getzenberg
Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness.
The Prostate 2012;72(9):966-76.
2012: Herbert Lepor; Leslie A Mangold; Daniel W Chan; Carol D Cheli; Juliana Laze; Lori J Sokoll; Samir S Taneja; Robert P Thiel; Alan W Partin
Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA(TM) , as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study.
BJU international 2012;109(12):1770-5.
2012: Anand P Chokkalingam; L W Chu; Angelo M DeMarzo; R N Hoover; A Adjei; Richard B Biritwum; D Chia; S Jadallah; Y Li; GEORGES NETTO; S Niwa; Alan W Partin; C Roehrborn; Y Tettey; Ian M Thompson; E D Yeboah; K Yu; Ann W Hsing
Prevalence of BPH and lower urinary tract symptoms in West Africans.
Prostate cancer and prostatic diseases 2012;15(2):170-6.
2012: Jeffrey K Mullins; Alan W Partin; Phillip M Pierorazio; Misop Han; H Ballentine Carter
Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer.
The Journal of urology 2012;187(5):1620-5.
2012: Alcides Chaux; Theodore L DeWeese; Mario A Eisenberger; Daniel A Fajardo; Nilda Gonzalez-Roibon; Alan W Partin; GEORGES NETTO
High-grade prostatic adenocarcinoma present in a single biopsy core is associated with increased extraprostatic extension, seminal vesicle invasion, and positive surgical margins at prostatectomy.
Urology 2012;79(4):863-8.
2012: Phillip M Pierorazio; Ashley E Ross; Jonathan I Epstein; Misop Han; Alan W Partin; Edward M Schaeffer
Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer.
BJU international 2012;109(7):988-93.
2012: Charles M Ewing; Kathleen E Wiley; Kimberly A Zuhlke; Waibhav D Tembe; Dorhyun Johng; Guifang Yan; Vijayalakshmi Shanmugam; David W Craig; James E Montie; William B Isaacs; Christiane M Robbins; Sarah D Isaacs; Chris Bizon; Anna M Ray; Yunfei Wang; Tyler Izatt; S Lilly Zheng; Marta Gielzak; Shripad Sinari; Alan W Partin; John D Carpten; Patrick C Walsh; Ethan M Lange; Jianfeng Xu; Kathleen Cooney
Germline mutations in HOXB13 and prostate-cancer risk.
The New England journal of medicine 2012;366(2):141-9.
2012: J Curtis Nickel; Jayabalan Nirmal; Alan W Partin; Dean Assimos; Michael K Brawer; Michael B Chancellor; Stacy Loeb; Ellen Shapiro
Best of the 2012 AUA Annual Meeting: Highlights From the 2012 American Urological Association Meeting, May 19-23, 2012, Atlanta, GA.
Reviews in urology 2012;14(3-4):90-103.
2012: Donna P Ankerst; Yuanyuan Liang; Martin G Sanda; Tim Koniarski; Alan W Partin; Lori J Sokoll; Robin J Leach; Jacob Kagan; Daniel W Chan; John T Wei; Ziding Feng; Ian M Thompson
Updating risk prediction tools: a case study in prostate cancer.
Biometrical journal. Biometrische Zeitschrift 2012;54(1):127-42.
2012: Emmanuel S Antonarakis; Elizabeth B Humphreys; Patrick C Walsh; Michael A Carducci; Zhaoyong Feng; Alan W Partin; Bruce J Trock; Mario A Eisenberger
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.
BJU international 2012;109(1):32-9.
2012: Abhinav Sidana; Bruce J Trock; Zhaoyong Feng; David J Hernandez; Alan W Partin; Surajit Saha; Jonathan I Epstein
Treatment decision-making for localized prostate cancer: what younger men choose and why.
The Prostate 2012;72(1):58-64.
2011: David H Wilson; Daniel W Chan; Lei Chang; Carol D Cheli; Evan P Ferrell; David R Fournier; David W Hanlon; Herbert Lepor; Alan W Partin; Purvish P Patel; Gail K Provuncher; Lori J Sokoll; Linan Song; Robert P Thiel; David C Duffy
Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology.
Clinical chemistry 2011;57(12):1712-21.
2011: Ryan P Kopp; Alan W Partin; Misop Han; Stephen J Freedland; Elizabeth Humphreys; J Kellogg Parsons
Obesity and prostate enlargement in men with localized prostate cancer.
BJU international 2011;108(11):1750-5.
2011: Joan S Ko; Patricia Landis; H Ballentine Carter; Alan W Partin
Effect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate cancer active surveillance participants.
BJU international 2011;108(11):1739-42.
2011: Antoun Toubaji; Patrick C Walsh; Alan W Partin; Elizabeth A Platz; Roula Albadine; Alcides Chaux; Angelo M DeMarzo; Jonathan I Epstein; Michael C Haffner; Misop Han; William B Isaacs; Tamara LEVIN Lotan; Alan K Meeker; George Netto
Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2011;24(11):1511-20.
2011: Kenneth S Tseng; Fadi Brimo; Jonathan I Epstein; Patricia Landis; Alan W Partin; H Ballentine Carter
Repeat prostate biopsies predict location of index cancer in an active surveillance cohort.
BJU international 2011;108(9):1415-20.
2011: Tamara LEVIN Lotan; GEORGES NETTO; Ben Ho Park; Alan W Partin; Siobhan Sutcliffe; Jianfeng Xu; David Esopi; Bora Gurel; Misop Han; Jessica L Hicks; Elizabeth Humphreys; William B Isaacs; Wennuan Liu; Angelo M DeMarzo
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(20):6563-73.
2011: Jacob Schwartzman; Lina Gao; Robert L Vessella; Motomi Mori; Luai Zarour; Shannon K McWeeney; Alan W Partin; Christopher L Corless; Solange Mongoue-Tchokote; Celestia Higano; Angela Gibbs; Lawrence True; Daniel Bottomly; Jennifer Jin; G Steven Bova; Beth Wilmot; Joshi Alumkal
A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer.
Epigenetics : official journal of the DNA Methylation Society 2011;6(10):1248-56.
2011: Ali Amin; Alan W Partin; Jonathan I Epstein
Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy.
The Journal of urology 2011;186(4):1286-90.
2011: Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(16):2185-90.
2011: Ahmed Magheli; Mark L Gonzalgo; Li-Ming Su; THOMAS GUZZO; George Netto; Elizabeth B Humphreys; Misop Han; Alan W Partin; Christian P Pavlovich
Impact of surgical technique (open vs laparoscopic vs robotic-assisted) on pathological and biochemical outcomes following radical prostatectomy: an analysis using propensity score matching.
BJU international 2011;107(12):1956-62.
2011: Lance A Mynderse; Claus G Roehrborn; Alan W Partin; Glenn M Preminger; Eric P Coté
Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasia.
The Journal of urology 2011;185(5):1804-10.
2011: Phillip M Pierorazio; Ashley E Ross; Edward M Schaeffer; Jonathan I Epstein; Misop Han; Patrick C Walsh; Alan W Partin
A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy.
The Journal of urology 2011;185(5):1691-7.
2011: William J Catalona; Alan W Partin; Martin G Sanda; John T Wei; George G Klee; Chris H Bangma; Kevin M Slawin; Leonard S Marks; Stacy Loeb; Dennis L Broyles; Sanghyuk S Shin; Amabelle B Cruz; Daniel W Chan; Lori J Sokoll; William L Roberts; Ron H N van Schaik; Isaac A Mizrahi
A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.
The Journal of urology 2011;185(5):1650-5.
2011: Ying Huang; Elizabeth Humphreys; Sumit Isharwal; Danil V Makarov; Alan W Partin; Felix K-H Chun; Jonathan I Epstein; Ziding Feng; Alexander Haese; Misop Han; Robert W Veltri
Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score.
BJU international 2011;107(10):1562-9.
2011: Scott E Eggener; Peter T Scardino; Patrick C Walsh; Misop Han; Alan W Partin; Bruce J Trock; Zhaoyong Feng; David P Wood; James A Eastham; Ofer Yossepowitch; Danny M Rabah; Michael W Kattan; Changhong Yu; Eric A Klein; Andrew J Stephenson
Predicting 15-year prostate cancer specific mortality after radical prostatectomy.
The Journal of urology 2011;185(3):869-75.
2011: Sumit Isharwal; Danil V Makarov; Lori J Sokoll; Patricia Landis; Cameron Marlow; Jonathan I Epstein; Alan W Partin; H Ballentine Carter; Robert W Veltri
ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.
Urology 2011;77(3):763.e1-6.
2011: Danil V Makarov; Stacy Loeb; Ahmed Magheli; Kevin Zhao; Elizabeth Humphreys; Mark L Gonzalgo; Alan W Partin; Misop Han
Significance of preoperative PSA velocity in men with low serum PSA and normal DRE.
World journal of urology 2011;29(1):11-4.
2011: Stacy Loeb; Alan W Partin
Review of the literature: PCA3 for prostate cancer risk assessment and prognostication.
Reviews in urology 2011;13(4):e191-5.
2011: Michael K Brawer; Michael B Chancellor; Stacy Loeb; J Curtis Nickel; Jayabalan Nirmal; Alan W Partin; Jacob Rajfer; Ellen Shapiro; Claus G Roehrborn
Best of the AUA Annual Meeting: Highlights From the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC.
Reviews in urology 2011;13(3):151-72.
2011: Stacy Loeb; Alan W Partin
Imaging utilization for the staging of clinically localized prostate cancer.
Reviews in urology 2011;13(1):63-4.
2010: Misop Han; Bruce J Trock; Alan W Partin; Elizabeth B Humphreys; Trinity J Bivalacqua; THOMAS GUZZO; Patrick C Walsh
The impact of preoperative erectile dysfunction on survival after radical prostatectomy.
BJU international 2010;106(11):1612-7.
2010: Fadi Brimo; Alan W Partin; Jonathan I Epstein
Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosis.
Urology 2010;76(5):1206-9.
2010: THOMAS GUZZO; Paul Dluzniewski; Ryan Orosco; Elizabeth A Platz; Alan W Partin; Misop Han
Prediction of mortality after radical prostatectomy by Charlson comorbidity index.
Urology 2010;76(3):553-7.
2010: Robert W Veltri; Sumit Isharwal; M Craig Miller; Jonathan I Epstein; Alan W Partin
Nuclear roundness variance predicts prostate cancer progression, metastasis, and death: A prospective evaluation with up to 25 years of follow-up after radical prostatectomy.
The Prostate 2010;70(12):1333-9.
2010: Phillip M Pierorazio; THOMAS GUZZO; Misop Han; Trinity J Bivalacqua; Jonathan I Epstein; Edward M Schaeffer; Mark P Schoenberg; Patrick C Walsh; Alan W Partin
Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen.
Urology 2010;76(3):715-21.
2010: Phillip M Pierorazio; Elizabeth B Humphreys; Patrick C Walsh; Alan W Partin; Misop Han
Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians.
BJU international 2010;106(6):791-5.
2010: Ashley E Ross; Stacy Loeb; Patricia Landis; Alan W Partin; Jonathan I Epstein; Anna Kettermann; Zhaoyong Feng; H Ballentine Carter; Patrick C Walsh
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(17):2810-6.
2010: Andrew J Armstrong; GEORGES NETTO; MICHELLE RUDEK-RENAUT; Susan Halabi; David P Wood Jr; Patricia A Creel; Kelly Mundy; S Lindsay Davis; Ting Wang; Roula Albadine; Luciana Schultz; Alan W Partin; Antonio Jimeno; Helen Fedor; Phillip G Febbo; Daniel J George; Robin Gurganus; Angelo M DeMarzo; Michael A Carducci
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(11):3057-66.
2010: Lori J Sokoll; Martin G Sanda; Ziding Feng; Jacob Kagan; Isaac A Mizrahi; Dennis L Broyles; Alan W Partin; Sudhir Srivastava; Ian M Thompson; John T Wei; Zhen Zhang; Daniel W Chan
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2010;19(5):1193-200.
2010: Jeffrey J Tosoian; Stacy Loeb; Anna Kettermann; Patricia Landis; Debra J Elliot; Jonathan I Epstein; Alan W Partin; H Ballentine Carter; Lori J Sokoll
Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.
The Journal of urology 2010;183(2):534-8.
2010: Sumit Isharwal; Danil V Makarov; H Ballentine Carter; Jonathan I Epstein; Alan W Partin; Patricia Landis; Cameron Marlow; Robert W Veltri
DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme.
BJU international 2010;105(3):329-33.
2010: Stacy Loeb; Alan W Partin
PCA3 Urinary Biomarker for Prostate Cancer.
Reviews in urology 2010;12(4):e205-6.
2010: Trinity J Bivalacqua; Stacy Loeb; Phillip M Pierorazio; Mark P Schoenberg; Alan W Partin; THOMAS GUZZO
Is prostate-specific antigen surveillance necessary in men with benign prostate pathology following radical cystoprostatectomy for bladder cancer?
Urologia internationalis 2010;85(4):466-9.
2010: Stacy Loeb; Alan W Partin
What is the true mortality benefit of prostate-specific antigen screening?
Reviews in urology 2010;12(1):66-7.
2010: Stacy Loeb; Alan W Partin
Open versus minimally invasive radical prostatectomy.
Reviews in urology 2010;12(1):64-5.
2010: Stacy Loeb; Alan W Partin; Edward M Schaeffer
Complications of pelvic lymphadenectomy: do the risks outweigh the benefits?
Reviews in urology 2010;12(1):20-4.
2010: Phillip M Pierorazio; Jonathan I Epstein; Elizabeth B Humphreys; Misop Han; Patrick C Walsh; Alan W Partin
The significance of a positive bladder neck margin after radical prostatectomy: the American Joint Committee on Cancer Pathological Stage T4 designation is not warranted.
The Journal of urology 2010;183(1):151-7.
2010: James B Yu; Danil V Makarov; Richa Sharma; Richard E Peschel; Alan W Partin; Cary P Gross
Validation of the partin nomogram for prostate cancer in a national sample.
The Journal of urology 2010;183(1):105-11.
2009: Danil V Makarov; Sumit Isharwal; Lori J Sokoll; Patricia Landis; Cameron Marlow; Jonathan I Epstein; Alan W Partin; H Ballentine Carter; Robert W Veltri
Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(23):7316-21.
2009: Emmanuel S Antonarakis; Elisabeth Iljas Heath; JANET WALCZAK; William G Nelson; Helen Fedor; Angelo M DeMarzo; Marianna L Zahurak; Steven Piantadosi; Andrew J Dannenberg; Robin T Gurganus; Sharyn D Baker; Howard L Parnes; Theodore L DeWeese; Alan W Partin; Michael A Carducci
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(30):4986-93.
2009: fianceeyi chun; Alexandre de la Taille; Hendrik van Poppel; Michael Marberger; Arnulf Stenzl; Peter F A Mulders; Hartwig Huland; Clement-Claude Abbou; Alexander B Stillebroer; Martijn P M Q van Gils; Jack A Schalken; Yves Fradet; Leonard S Marks; William Ellis; Alan W Partin; Alexander Haese
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.
European urology 2009;56(4):659-67.
2009: Alka Jain; Dianalee A McKnight; Larry W Fisher; Elizabeth B Humphreys; Leslie A Mangold; Alan W Partin; Neal S Fedarko
Small integrin-binding proteins as serum markers for prostate cancer detection.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(16):5199-207.
2009: Lionel L Bañez; Leon Sun; Bruce J Trock; Misop Han; Alan W Partin; William J Aronson; Martha Kennedy Terris; Joseph C Presti; Christopher J Kane; Christopher L Amling; Judd W Moul; Stephen J Freedland
Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
The Journal of urology 2009;182(2):491-6; discussion 496-8.
2009: A Karim Kader; Jielin Sun; Sarah D Isaacs; Kathy E Wiley; Guifang Yan; Seong-Tae Kim; Helen Fedor; Angelo M DeMarzo; Jonathan I Epstein; Patrick C Walsh; Alan W Partin; Bruce J Trock; S Lilly Zheng; Jianfeng Xu; William B Isaacs
Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
The Prostate 2009;69(11):1195-205.
2009: Eddy S Leman; Ahmed Magheli; Grant W Cannon; Leslie A Mangold; Alan W Partin; Robert H Getzenberg
Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2.
The Prostate 2009;69(11):1188-94.
2009: Sumit Isharwal; M Craig Miller; Jonathan I Epstein; Leslie A Mangold; Elizabeth Humphreys; Alan W Partin; Robert W Veltri
DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction.
Urology 2009;73(5):1092-7.
2009: CAROLYN ROSENZWEIG; Zhen Zhang; Xiaer Sun; Lori J Sokoll; Katherine Osborne; Alan W Partin; Daniel W Chan
Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers.
The Journal of urology 2009;181(3):1407-14.
2009: David J Hernandez; Misop Han; Elizabeth B Humphreys; Leslie A Mangold; Samir S Taneja; Stacy J Childs; Georg Bartsch; Alan W Partin
Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone.
BJU international 2009;103(5):609-14.
2009: Kazutoshi Fujita; Charles M Ewing; David Y Chan; Leslie A Mangold; Alan W Partin; William B Isaacs; Christian P Pavlovich
Endoglin (CD105) as a urinary and serum marker of prostate cancer.
International journal of cancer. Journal international du cancer 2009;124(3):664-9.
2009: Stacy Loeb; Alan W Partin
Randomized trials of prostate cancer screening.
Reviews in urology 2009;11(3):179-80.
2009: Stacy Loeb; Alan W Partin
Randomized trials of selenium, vitamin e, or vitamin C for prostate cancer prevention.
Reviews in urology 2009;11(2):114-5.
2009: Michael K Brawer; Stacy Loeb; Alan W Partin; Naoki Yoshimura; Michael B Chancellor; Claus G Roehrborn; Dean G Assimos; J Curtis Nickel; B Shuch; F Pouliot; Arie S Belldegrun; Ellen Shapiro
Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.
Reviews in urology 2009;11(2):82-107.
2009: Pierre C Mozer; Alan W Partin; Dan Stoianovici
Robotic image-guided needle interventions of the prostate.
Reviews in urology 2009;11(1):7-15.
2009: Rong Hu; Thomas A Dunn; Shuanzeng Wei; Sumit Isharwal; Robert W Veltri; Elizabeth Humphreys; Misop Han; Alan W Partin; Robert L Vessella; William B Isaacs; G Steven Bova; Jun Luo
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.
Cancer research 2009;69(1):16-22.
2009: Danil V Makarov; Stacy Loeb; Robert H Getzenberg; Alan W Partin
Biomarkers for prostate cancer.
Annual review of medicine 2009;60():139-51.
2008: Sumit Isharwal; Michael Craig Miller; Jonathan I Epstein; Leslie A Mangold; Elizabeth Humphreys; Alan W Partin; Robert W Veltri
Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy.
International journal of cancer. Journal international du cancer 2008;123(11):2636-43.
2008: Robert W Veltri; Sumit Isharwal; M Craig Miller; Jonathan I Epstein; Leslie A Mangold; Elizabeth Humphreys; Alan W Partin
Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis.
The Prostate 2008;68(16):1806-15.
2008: Joshi J Alumkal; Zhe Zhang; Elizabeth B Humphreys; Christina Bennett; Leslie A Mangold; Michael A Carducci; Alan W Partin; Elizabeth Garrett-Mayer; Angelo M DeMarzo; James G Herman
Effect of DNA methylation on identification of aggressive prostate cancer.
Urology 2008;72(6):1234-9.
2008: Ahmed Magheli; Soroush Rais-Bahrami; Bruce J Trock; Elizabeth B Humphreys; Alan W Partin; Misop Han; Mark L Gonzalgo
Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching.
Urology 2008;72(6):1246-51.
2008: Ina Wu; Matthew Nielsen; Misop Han; Alan W Partin; Danil V Makarov
Does laterality of positive needle biopsy in clinical T2a patients with prostate cancer affect biochemical recurrence-free survival?
Urology 2008;72(6):1219-23.
2008: Jielin Sun; Siqun Lilly Zheng; Fredrik Wiklund; Sarah D Isaacs; Lina D Purcell; Zhengrong Gao; Fang-Chi Hsu; Seong-Tae Kim; Wennuan Liu; Yi Zhu; Pär Stattin; Hans-Olov Adami; Kathleen E Wiley; Latchezar Dimitrov; Jishan Sun; Tao Li; Aubrey R Turner; Tamara S Adams; Jan Adolfsson; Jan-Erik Johansson; James Lowey; Bruce J Trock; Alan W Partin; Patrick C Walsh; Jeffrey M. Trent; David Duggan; John Carpten; Bao-Li Chang; Henrik Grönberg; William B Isaacs; Jianfeng Xu
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12.
Nature genetics 2008;40(10):1153-5.
2008: Jianfeng Xu; Sarah D Isaacs; Jielin Sun; Ge Li; Kathleen E Wiley; Yi Zhu; Fang-Chi Hsu; Fredrik Wiklund; Aubrey R Turner; Tamara S Adams; Wennuan Liu; Bruce J Trock; Alan W Partin; Baoli Chang; Patrick C Walsh; Henrik Grönberg; William B Isaacs; Siqun Zheng
Association of prostate cancer risk variants with clinicopathologic characteristics of the disease.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5819-24.
2008: Jielin Sun; Bao-Li Chang; Sarah D Isaacs; Kathy E Wiley; Fredrik Wiklund; Pär Stattin; David Duggan; John D Carpten; Bruce J Trock; Alan W Partin; Patrick C Walsh; Henrik Grönberg; Jianfeng Xu; William B Isaacs; S Lilly Zheng
Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations.
The Prostate 2008;68(12):1257-62.
2008: Lori J Sokoll; Yinghui Wang; Ziding Feng; Jacob Kagan; Alan W Partin; Martin G Sanda; Ian M Thompson; Daniel W Chan
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.
The Journal of urology 2008;180(2):539-43; discussion 543.
2008: Kevin H Zhao; David J Hernandez; Misop Han; Elizabeth B Humphreys; Leslie A Mangold; Alan W Partin
External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score.
Urology 2008;72(2):396-400.
2008: Matthew Nielsen; Danil V Makarov; Elizabeth B Humphreys; Leslie A Mangold; Alan W Partin; Patrick C Walsh
Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?
Urology 2008;72(2):389-93; discussion 394-5.
2008: Sumit Isharwal; M Craig Miller; Cameron Marlow; Danil V Makarov; Alan W Partin; Robert W Veltri
p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape.
The Prostate 2008;68(10):1097-104.
2008: David J Hernandez; Matthew Nielsen; Misop Han; Bruce J Trock; Alan W Partin; Patrick C Walsh; Jonathan I Epstein
Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy.
Urology 2008;72(1):172-6.
2008: Bruce J Trock; Misop Han; Stephen J Freedland; Elizabeth B Humphreys; Theodore L DeWeese; Alan W Partin; Patrick C Walsh
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.
JAMA : the journal of the American Medical Association 2008;299(23):2760-9.
2008: Ghil-Suk Yoon; Wenle Wang; Adeboye O Osunkoya; Zhaoli Lane; Alan W Partin; Jonathan I Epstein
Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma.
The Journal of urology 2008;179(6):2203-6; discussion 2206.
2008: Stacy Loeb; David J Hernandez; Leslie A Mangold; Elizabeth B Humphreys; Marilyn Agro; Patrick C Walsh; Alan W Partin; Misop Han
Progression after radical prostatectomy for men in their thirties compared to older men.
BJU international 2008;101(12):1503-6.
2008: Jielin Sun; Lina Purcell; Zhengrong Gao; Sarah D Isaacs; Kathy E Wiley; Fang-Chi Hsu; Wennuan Liu; David Duggan; John D Carpten; Henrik Grönberg; Jianfeng Xu; Bao-Li Chang; Alan W Partin; Patrick C Walsh; William B Isaacs; S Lilly Zheng
Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans.
The Prostate 2008;68(7):691-7.
2008: Ahmed Magheli; Soroush Rais-Bahrami; Bruce J Trock; Elizabeth B Humphreys; Alan W Partin; Misop Han; Mark L Gonzalgo
Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy.
The Journal of urology 2008;179(5):1780-4; discussion 1784.
2008: Ina L Deras; Sheila M J Aubin; Amy Blase; John R Day; Seongjoon Koo; Alan W Partin; William J Ellis; Leonard S Marks; Yves Fradet; Harry Rittenhouse; Jack Groskopf
PCA3: a molecular urine assay for predicting prostate biopsy outcome.
The Journal of urology 2008;179(4):1587-92.
2008: Michael Müntener; Jonathan I Epstein; David J Hernandez; Mark L Gonzalgo; Leslie A Mangold; Elizabeth B Humphreys; Patrick C Walsh; Alan W Partin; Matthew Nielsen
Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy.
European urology 2008;53(4):767-75; discussion 775-6.
2008: Julius Gudmundsson; Patrick Sulem; Thorunn Rafnar; Jon T Bergthorsson; Andrei Manolescu; Daniel Gudbjartsson; Bjarni A Agnarsson; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Thorarinn Blondal; Margret Jakobsdottir; Simon N Stacey; Jelena Kostic; Kari T Kristinsson; Birgitta Birgisdottir; Shyamali Ghosh; Droplaug N Magnusdottir; Steinunn Thorlacius; Gudmar Thorleifsson; S Lilly Zheng; Jielin Sun; Bao-Li Chang; J Bradford Elmore; Joan P Breyer; Kate M McReynolds; Kevin M Bradley; Brian Yaspan; Fredrik Wiklund; Par Stattin; Sara Lindström; Hans-Olov Adami; Shannon K McDonnell; Daniel J Schaid; Julie M Cunningham; Liang Wang; James R Cerhan; Jennifer L St Sauver; Sara D Isaacs; Kathleen E Wiley; Alan W Partin; Patrick C Walsh; Sonia Polo; Manuel Ruiz-Echarri; Sebastian Navarrete; Fernando Fuertes; Berta Saez; Javier Godino; Philip C Weijerman; Dorine W Swinkels; Katja K Aben; J Alfred Witjes; Brian K Suarez; Brian T Helfand; Michael L Frigge; Kristleifur Kristjansson; Carole Ober; Eirikur Jonsson; Gudmundur V Einarsson; Jianfeng Xu; Henrik Gronberg; Jeffrey R Smith; Stephen N Thibodeau; William B Isaacs; William J Catalona; Jose I Mayordomo; Lambertus A Kiemeney; Rosa B Barkardottir; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; kari stefansson
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer.
Nature genetics 2008;40(3):281-3.
2008: Danil V Makarov; Cameron Marlow; Jonathan I Epstein; M Craig Miller; Patricia Landis; Alan W Partin; H Ballentine Carter; Robert W Veltri
Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent.
The Prostate 2008;68(2):183-9.
2008: Patrick J Bastian; Ganesh S Palapattu; Srinivasan Yegnasubramanian; Craig G Rogers; Xiaohui Lin; Leslie A Mangold; Bruce J Trock; Mario A Eisenberger; Alan W Partin; William G Nelson
CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer.
The Journal of urology 2008;179(2):529-34; discussion 534-5.
2008: Stacy Loeb; Alan W Partin
Single nucleotide polymorphisms and prostate cancer susceptibility.
Reviews in urology 2008;10(4):304-5.
2008: Danil V Makarov; Alan W Partin
Weighing the risks: prostate cancer versus cardiovascular disease.
Reviews in urology 2008;10(2):171-3.
2008: Michael K Brawer; Danil V Makarov; Alan W Partin; Claus G Roehrborn; J Curtis Nickel; Shing-Hwa Lu; Naoki Yoshimura; Michael B Chancellor; Dean G Assimos
Best of the 2008 AUA Annual Meeting: Highlights from the 2008 Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FL.
Reviews in urology 2008;10(2):136-56.
2008: Danil V Makarov; Alan W Partin
Focal therapy for prostate cancer.
Reviews in urology 2008;10(1):81-2.
2008: Robert W Veltri; M Craig Miller; Sumit Isharwal; Cameron Marlow; Danil V Makarov; Alan W Partin
Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008;17(1):102-10.
2008: Dale McLerran; William E Grizzle; Ziding Feng; Ian M Thompson; William L Bigbee; Lisa H Cazares; Daniel W Chan; Jackie Dahlgren; Jose Diaz; Jacob Kagan; Daniel W Lin; Gunjan Malik; Denise Oelschlager; Alan W Partin; Timothy W Randolph; Lori J Sokoll; sudhir srivastava; Sudhir Srivastava; Mark D Thornquist; Dean A Troyer; George L Wright; Zhen Zhang; Liu Zhu; O John Semmes
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.
Clinical chemistry 2008;54(1):53-60.
2008: Danil V Makarov; Elizabeth B Humphreys; Leslie A Mangold; Michael A Carducci; Alan W Partin; Mario A Eisenberger; Patrick C Walsh; Bruce J Trock
The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy.
The Journal of urology 2008;179(1):156-61; discussion 161-2.
2008: Dale McLerran; William E Grizzle; Ziding Feng; William L Bigbee; Lionel L Banez; Lisa H Cazares; Daniel W Chan; Jose Diaz; Elzbieta Izbicka; Jacob Kagan; David E Malehorn; Gunjan Malik; Denise Oelschlager; Alan W Partin; Timothy W Randolph; Nicole Rosenzweig; sudhir srivastava; Sudhir Srivastava; Ian M Thompson; Mark D Thornquist; Dean A Troyer; Yutaka Yasui; Zhen Zhang; Liu Zhu; O John Semmes
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.
Clinical chemistry 2008;54(1):44-52.
2007: David Duggan; Siqun L Zheng; Michele Knowlton; Debbie Benitez; Latchezar Dimitrov; Fredrik Wiklund; Christiane Robbins; Sarah D Isaacs; Yu Cheng; Ge Li; Jielin Sun; Bao-Li Chang; Leslie Marovich; Kathleen E Wiley; Katarina Bälter; Pär Stattin; Hans-Olov Adami; Marta Gielzak; Guifang Yan; Jurga Sauvageot; Wennuan Liu; Jin Woo Kim; Eugene R Bleecker; Deborah A Meyers; Bruce J Trock; Alan W Partin; Patrick C Walsh; William B Isaacs; Henrik Grönberg; Jianfeng Xu; John D Carpten
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP.
Journal of the National Cancer Institute 2007;99(24):1836-44.
2007: Lionel L Bañez; Robert J Hamilton; Alan W Partin; Robin T Vollmer; Leon Sun; Carmen Rodriguez; Yiting Wang; Martha Kennedy Terris; William J Aronson; Joseph C Presti; Christopher J Kane; Christopher L Amling; Judd W Moul; Stephen J Freedland
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
JAMA : the journal of the American Medical Association 2007;298(19):2275-80.
2007: David J Hernandez; Matthew Nielsen; Misop Han; Alan W Partin
Contemporary evaluation of the D'amico risk classification of prostate cancer.
Urology 2007;70(5):931-5.
2007: S Lilly Zheng; Jielin Sun; Yu Cheng; Ge Li; Fang-Chi Hsu; Yi Zhu; Bao-Li Chang; Wennuan Liu; Jin Woo Kim; Aubrey R Turner; Marta Gielzak; Guifang Yan; Sarah D Isaacs; Kathy E Wiley; Jurga Sauvageot; Huann-Sheng Chen; Robin Gurganus; Leslie A Mangold; Bruce J Trock; Henrik Gronberg; David Duggan; John D Carpten; Alan W Partin; Patrick C Walsh; Jianfeng Xu; William B Isaacs
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans.
Journal of the National Cancer Institute 2007;99(20):1525-33.
2007: Gunjan Malik; Elizabeth Rojahn; Michael D Ward; Matthew B Gretzer; Alan W Partin; O John Semmes; Robert W Veltri
SELDI protein profiling of dunning R-3327 derived cell lines: identification of molecular markers of prostate cancer progression.
The Prostate 2007;67(14):1565-75.
2007: Patrick J Bastian; Ganesh S Palapattu; Srinivasan Yegnasubramanian; Xiaohui Lin; Craig G Rogers; Leslie A Mangold; Bruce J Trock; Mario A Eisenberger; Alan W Partin; William G Nelson
Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5361-7.
2007: Connie Collins; Michael A Carducci; Mario A Eisenberger; John T Isaacs; Alan W Partin; Roberto Pili; Victoria Sinibaldi; JANET WALCZAK; Samuel R Denmeade
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.
Cancer biology & therapy 2007;6(9):1360-7.
2007: B Djavan; S Marihart; F Kuehhas; M Rom; Alan W Partin; J Schalken; T Sekeres
[Resveratrol and newly synthetized resveratrol analogs in therapy of prostate carcinoma].
Der Urologe. Ausg. A 2007;46(9):1101-3.
2007: Robert W Veltri; Cameron Marlow; Masood A Khan; M Craig Miller; Jonathan I Epstein; Alan W Partin
Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysis.
The Prostate 2007;67(11):1202-10.
2007: John C Mavropoulos; Alan W Partin; Christopher L Amling; Martha Kennedy Terris; Christopher J Kane; William J Aronson; Joseph C Presti; Leslie A Mangold; Stephen J Freedland
Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men?
Urology 2007;69(6):1138-42.
2007: Danil V Makarov; Bruce J Trock; Elizabeth B Humphreys; Leslie A Mangold; Patrick C Walsh; Jonathan I Epstein; Alan W Partin
Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.
Urology 2007;69(6):1095-101.
2007: Sara Forrester; Ji Qiu; Leslie Mangold; Alan W Partin; David E Misek; Brett Phinney; Douglas Whitten; Philip C Andrews; Eleftherios Diamandis; Gilbert S Omenn; Samir Hanash; Brian B Haab
An experimental strategy for quantitative analysis of the humoral immune response to prostate cancer antigens using natural protein microarrays.
Proteomics. Clinical applications 2007;1(5):494-505.
2007: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario A Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(13):1765-71.
2007: Adam S Kibel; Eli Rosenbaum; Michael W Kattan; Joel Picus; Robert Dreicer; Eric A Klein; Gurkamal S Chatta; Joel B Nelson; Robert S DiPaola; Bruce J Roth; Michael S Cookson; George Wilding; David F Jarrard; Tomasz M Beer; Christopher W Ryan; Daniel P Petrylak; Mitchell C Benson; Alan W Partin; Elizabeth Garrett-Mayer; Mario A Eisenberger
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
The Journal of urology 2007;177(5):1777-81.
2007: D E Hansel; Angelo M DeMarzo; Elizabeth A Platz; S Jadallah; J Hicks; Jonathan I Epstein; Alan W Partin; GEORGES NETTO
Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
The Journal of urology 2007;177(5):1736-40.
2007: Julius Gudmundsson; Patrick Sulem; Andrei Manolescu; Laufey T Amundadottir; Daniel Gudbjartsson; Agnar Helgason; Thorunn Rafnar; Jon T Bergthorsson; Bjarni A Agnarsson; Adam Baker; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Margret Jakobsdottir; Jianfeng Xu; Thorarinn Blondal; Jelena Kostic; Jielin Sun; Shyamali Ghosh; Simon N Stacey; Magali Mouy; Jona Saemundsdottir; Valgerdur M Backman; Kristleifur Kristjansson; Alejandro Tres; Alan W Partin; Marjo T Albers-Akkers; Javier Godino-Ivan Marcos; Patrick C Walsh; Dorine W Swinkels; Sebastian Navarrete; Sarah D Isaacs; Katja K Aben; Theresa Graif; John Cashy; Manuel Ruiz-Echarri; Kathleen E Wiley; Brian K Suarez; J Alfred Witjes; Mike Frigge; Carole Ober; Eirikur Jonsson; Gudmundur V Einarsson; Jose I Mayordomo; Lambertus A Kiemeney; William B Isaacs; William J Catalona; Rosa B Barkardottir; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; kari stefansson
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.
Nature genetics 2007;39(5):631-7.
2007: Eddy S Leman; Grant W Cannon; Bruce J Trock; Lori J Sokoll; Daniel W Chan; Leslie A Mangold; Alan W Partin; Robert H Getzenberg
EPCA-2: a highly specific serum marker for prostate cancer.
Urology 2007;69(4):714-20.
2007: J Kellogg Parsons; Alan W Partin; Bruce J Trock; Debra J Bruzek; Carol D Cheli; Lori J Sokoll
Complexed prostate-specific antigen for the diagnosis of biochemical recurrence after radical prostatectomy.
BJU international 2007;99(4):758-61.
2007: Stephen J Freedland; Alan W Partin; Elizabeth B Humphreys; Leslie A Mangold; Patrick C Walsh
Radical prostatectomy for clinical stage T3a disease.
Cancer 2007;109(7):1273-8.
2007: Michael W Shafer; Leslie Mangold; Alan W Partin; Brian B Haab
Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease.
The Prostate 2007;67(3):255-67.
2007: Michael K Brawer; Danil V Makarov; Alan W Partin; Claus G Roehrborn; J Curtis Nickel; Michael B Chancellor; Dean G Assimos; Ellen Shapiro; Jacob Rajfer
Best of the 2007 AUA Annual Meeting: Highlights from the 2007 Annual Meeting of the American Urological Association, May 19-24, 2007, Anaheim, CA.
Reviews in urology 2007;9(3):133-54.
2007: Danil V Makarov; Alan W Partin
Prostate-Cancer Risk Stratification via Early PSA Testing.
Reviews in urology 2007;9(2):91-2.
2007: Matthew Nielsen; Alan W Partin
The impact of definitions of failure on the interpretation of biochemical recurrence following treatment of clinically localized prostate cancer.
Reviews in urology 2007;9(2):57-62.
2007: Danil V Makarov; Alan W Partin
Postprostatectomy risk stratification based on detection of occult lymph node metastasis.
Reviews in urology 2007;9(1):41-3.
2006: Leonard S Marks; Norman A Mazer; Elahe A Mostaghel; David L Hess; Frederick J Dorey; Jonathan I Epstein; Robert W Veltri; Danil V Makarov; Alan W Partin; David G Bostwick; Maria Luz Macairan; Peter S Nelson
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2006;296(19):2351-61.
2006: Robert W Veltri; Masood A Khan; Cameron Marlow; M Craig Miller; Stephen D Mikolajczyk; Munekado Kojima; Alan W Partin; Leonard S Marks
Alterations in nuclear structure and expression of proPSA predict differences between native Japanese and Japanese-American prostate cancer.
Urology 2006;68(4):898-904.
2006: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario A Eisenberger; Alan W Partin
Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
The Journal of urology 2006;176(4 Pt 1):1404-8.
2006: Patrick J Bastian; Mark L Gonzalgo; William J Aronson; Martha Kennedy Terris; Christopher J Kane; Christopher L Amling; Joseph C Presti; Leslie A Mangold; Elizabeth B Humphreys; Jonathan I Epstein; Alan W Partin; Stephen J Freedland
Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Cancer 2006;107(6):1265-72.
2006: Danil V Makarov; Elizabeth B Humphreys; Leslie A Mangold; Patrick C Walsh; Alan W Partin; Jonathan I Epstein; Stephen J Freedland
Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
The Journal of urology 2006;176(2):554-8.
2006: Matthew Nielsen; Misop Han; Leslie A Mangold; Elizabeth B Humphreys; Patrick C Walsh; Alan W Partin; Stephen J Freedland
Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center.
The Journal of urology 2006;176(2):515-9.
2006: Sabine Rohrmann; MARGARET D FALLIN; William F Page; Terry Reed; Alan W Partin; Patrick C Walsh; Elizabeth A Platz
Concordance rates and modifiable risk factors for lower urinary tract symptoms in twins.
Epidemiology (Cambridge, Mass.) 2006;17(4):419-27.
2006: J Kellogg Parsons; H Ballentine Carter; Alan W Partin; B Gwen Windham; E Jeffrey Metter; Luigi Ferrucci; Patricia Landis; Elizabeth A Platz
Metabolic factors associated with benign prostatic hyperplasia.
The Journal of clinical endocrinology and metabolism 2006;91(7):2562-8.
2006: J Kellogg Parsons; Alan W Partin
Clinical interpretation of prostate biopsy reports.
Urology 2006;67(3):452-7.
2006: Stephen J Freedland; Alan W Partin
Prostate-specific antigen: update 2006.
Urology 2006;67(3):458-60.
2006: Sabine Rohrmann; MARGARET D FALLIN; William F Page; Terry Reed; Alan W Partin; Patrick C Walsh; Elizabeth A Platz
Re: "Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish twin registry".
International journal of cancer. Journal international du cancer 2006;118(3):785.
2006: Danil V Makarov; Alan W Partin
Conflicting insights into the role of watchful waiting in the management of adenocarcinoma of the prostate.
Reviews in urology 2006;8(4):232-4.
2006: Mohamad E Allaf; Alan W Partin; H Ballentine Carter
The importance of pelvic lymph node dissection in men with clinically localized prostate cancer.
Reviews in urology 2006;8(3):112-9.
2006: Danil V Makarov; Alan W Partin
Translation research in prostate cancer.
Reviews in urology 2006;8(2):89-91.
2006: Danil V Makarov; Alan W Partin
The predictive capability of prostate-specific antigen kinetics.
Reviews in urology 2006;8(1):41-3.
2006: Mark L Gonzalgo; Patrick J Bastian; Leslie A Mangold; Bruce J Trock; Jonathan I Epstein; Patrick C Walsh; Alan W Partin
Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate.
Urology 2006;67(1):115-9.
2005: Eli Rosenbaum; Mohammad Hoque; Yoram Cohen; Marianna Zahurak; Mario A Eisenberger; Jonathan I Epstein; Alan W Partin; David Sidransky
Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(23):8321-5.
2005: Christopher L Wu; Andrew J Rowlingson; Alan W Partin; Murray A Kalish; Genevieve E Courpas; Patrick C Walsh; Lee A Fleisher
Correlation of postoperative pain to quality of recovery in the immediate postoperative period.
Regional anesthesia and pain medicine 2005;30(6):516-22.
2005: J Kellogg Parsons; Alan W Partin
Hugh Hampton Young, benign prostatic hyperplasia, and "the cure of prostatic obstruction".
Journal of the American College of Surgeons 2005;201(5):654-5.
2005: Stephen J Freedland; Kelly A Grubb; Sindy K Yiu; Matthew Nielsen; Leslie A Mangold; William B Isaacs; Jonathan I Epstein; Alan W Partin
Obesity and capsular incision at the time of open retropubic radical prostatectomy.
The Journal of urology 2005;174(5):1798-801; discussion 1801.
2005: Stephen J Freedland; Leslie A Mangold; Patrick C Walsh; Alan W Partin
The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy.
The Journal of urology 2005;174(4 Pt 1):1276-81; discussion 1281; author reply 1281.
2005: Stephen J Freedland; Lori J Sokoll; Elizabeth A Platz; Leslie A Mangold; Debra J Bruzek; Phaedre Mohr; Sindy K Yiu; Alan W Partin
Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy.
The Journal of urology 2005;174(4 Pt 1):1266-70.
2005: Alexander M Truskinovsky; Alan W Partin; Martin H Kroll
Kinetics of tumor growth of prostate carcinoma estimated using prostate-specific antigen.
Urology 2005;66(3):577-81.
2005: Stephen J Freedland; Kelly A Grubb; Sindy K Yiu; Elizabeth B Humphreys; Matthew Nielsen; Leslie A Mangold; William B Isaacs; Alan W Partin
Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center.
The Journal of urology 2005;174(3):919-22.
2005: Christopher L Wu; Alan W Partin; Andrew J Rowlingson; Murray A Kalish; Patrick C Walsh; Lee A Fleisher
Efficacy of continuous local anesthetic infusion for postoperative pain after radical retropubic prostatectomy.
Urology 2005;66(2):366-70.
2005: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario A Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.
JAMA : the journal of the American Medical Association 2005;294(4):433-9.
2005: Patrick J Bastian; Ganesh S Palapattu; Xiaohui Lin; Srinivasan Yegnasubramanian; Leslie A Mangold; Bruce J Trock; Mario A Eisenberger; Alan W Partin; William G Nelson
Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(11):4037-43.
2005: L M Ellison; Bruce J Trock; N R Poe; Alan W Partin
The effect of hospital volume on cancer control after radical prostatectomy.
The Journal of urology 2005;173(6):2094-8.
2005: Stephen J Freedland; William B Isaacs; Leslie A Mangold; Sindy K Yiu; Kelly A Grubb; Alan W Partin; Jonathan I Epstein; Patrick C Walsh; Elizabeth A Platz
Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(8):2883-8.
2005: Stephen J Freedland; Lori J Sokoll; Leslie A Mangold; Debra J Bruzek; Phaedre Mohr; Sindy K Yiu; Jonathan I Epstein; Alan W Partin
Serum leptin and pathological findings at the time of radical prostatectomy.
The Journal of urology 2005;173(3):773-6.
2005: Alexander Haese; Ville Vaisanen; Hans Lilja; Michael W Kattan; Harry G Rittenhouse; Kim Pettersson; Daniel W Chan; Hartwig Huland; Lori J Sokoll; Alan W Partin
Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
The Journal of urology 2005;173(3):752-6.
2005: Masood A Khan; Alan W Partin
Surgical margin status after radical retropubic prostatectomy.
BJU international 2005;95(3):281-4.
2005: Stephen J Freedland; Alan W Partin
Detecting Prostate Cancer with Molecular Markers: uPM3.
Reviews in urology 2005;7(4):236-8.
2005: Stephen J Freedland; Alan W Partin
Early hormonal therapy for prostate cancer: the good, the bad, and the ugly.
Reviews in urology 2005;7(3):187-9.
2005: Stephen J Freedland; Alan W Partin
Dawning of the age of chemotherapy for prostate cancer.
Reviews in urology 2005;7(2):110-2.
2005: Stephen J Freedland; Alan W Partin
Optimal surgical management of the obese man with prostate cancer: laparoscopic or perineal radical prostatectomy.
Reviews in urology 2005;7(1):46-7.
2005: Stephen J Freedland; Alan W Partin
Prostate cancer update: 2004: highlights from the 4th international prostate cancer congress, grand bahama island, bahamas, july 15-18, 2004.
Reviews in urology 2005;7(1):41-5.
2005: Masood A Khan; Alan W Partin
Expectant management: an option for localized prostate cancer.
Prostate cancer and prostatic diseases 2005;8(4):311-5.
2005: O John Semmes; Ziding Feng; Bao-Ling Adam; Lionel L Banez; William L Bigbee; David Campos; Lisa H Cazares; Daniel W Chan; William E Grizzle; Elzbieta Izbicka; Jacob Kagan; Gunjan Malik; Dale McLerran; Judd W Moul; Alan W Partin; Premkala Prasanna; Jason Rosenzweig; Lori J Sokoll; sudhir srivastava; Sudhir Srivastava; Ian M Thompson; Manda J Welsh; Nicole White; Marcy Winget; Yutaka Yasui; Zhen Zhang; Liu Zhu
Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.
Clinical chemistry 2005;51(1):102-12.
2004: Masood A Khan; Michael A Carducci; Alan W Partin
Docetaxel in androgen-independent prostate cancer: an update.
BJU international 2004;94(9):1209-10.
2004: Masood A Khan; Lori J Sokoll; Daniel W Chan; Leslie A Mangold; Phaedre Mohr; Stephen D Mikolajczyk; Harry J Linton; Cindy L Evans; Harry G Rittenhouse; Alan W Partin
Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
Urology 2004;64(6):1160-4.
2004: Craig G Rogers; Masood A Khan; M Craig Miller; Robert W Veltri; Alan W Partin
Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Cancer 2004;101(11):2549-56.
2004: Masood A Khan; Leslie A Mangold; Jonathan I Epstein; John K Boitnott; Patrick C Walsh; Alan W Partin
Impact of surgical delay on long-term cancer control for clinically localized prostate cancer.
The Journal of urology 2004;172(5 Pt 1):1835-9.
2004: Patrick J Bastian; Leslie A Mangold; Jonathan I Epstein; Alan W Partin
Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis.
Cancer 2004;101(9):2001-5.
2004: Dennis A Faith; William B Isaacs; James D Morgan; Helen Fedor; Jessica L Hicks; Leslie A Mangold; Patrick C Walsh; Alan W Partin; Elizabeth A Platz; Jun Luo; Angelo M DeMarzo
Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays.
The Prostate 2004;61(3):215-27.
2004: Leonard S Marks; Munekado Kojima; Angelo M DeMarzo; David Heber; David G Bostwick; Junqi Qian; Frederick J Dorey; Robert W Veltri; James L Mohler; Alan W Partin
Prostate cancer in native Japanese and Japanese-American men: effects of dietary differences on prostatic tissue.
Urology 2004;64(4):765-71.
2004: Hakan Aydin; Toyonori Tsuzuki; David Hernandez; Patrick C Walsh; Alan W Partin; Jonathan I Epstein
Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression.
Urology 2004;64(3):551-5.
2004: Matthew B Gretzer; Daniel W Chan; C L van Rootselaar; Jason Rosenzweig; S Dalrymple; Leslie A Mangold; Alan W Partin; Robert W Veltri
Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF.
The Prostate 2004;60(4):325-31.
2004: Mario A Eisenberger; Alan W Partin
Progress toward identifying aggressive prostate cancer.
The New England journal of medicine 2004;351(2):180-1.
2004: J Kellogg Parsons; Michael K Brawer; Carol D Cheli; Alan W Partin; Robert Djavan
Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.
BJU international 2004;94(1):47-50.
2004: Masood A Khan; Alan W Partin
Management of patients with an increasing prostate-specific antigen after radical prostatectomy.
Current urology reports 2004;5(3):179-87.
2004: Robert W Veltri; Masood A Khan; M Craig Miller; Jonathan I Epstein; Leslie A Mangold; Patrick C Walsh; Alan W Partin
Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3465-73.
2004: Eli Rosenbaum; Alan W Partin; Mario A Eisenberger
Biochemical relapse after primary treatment for prostate cancer: studies on natural history and therapeutic considerations.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2(3):249-56.
2004: Stephen J Freedland; Leslie A Mangold; Jonathan I Epstein; Alan W Partin
Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
Urology 2004;63(5):887-91.
2004: J Kellogg Parsons; Alan W Partin
Applying complexed prostate-specific antigen to clinical practice.
Urology 2004;63(5):815-8.
2004: Jinong Li; Nicole White; Zhen Zhang; Jason Rosenzweig; Leslie A Mangold; Alan W Partin; Daniel W Chan
Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population.
The Journal of urology 2004;171(5):1782-7.
2004: Stephen J Freedland; Alan W Partin; Jonathan I Epstein; Patrick C Walsh
Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.
Cancer 2004;100(8):1646-9.
2004: Bruce J Trock; Michelle Brotzman; William J Utz; Roland R Ugarte; Steven A Kaplan; Thayne R Larson; Michael L Blute; Claus G Roehrborn; Alan W Partin
Long-term pooled analysis of multicenter studies of cooled thermotherapy for benign prostatic hyperplasia results at three months through four years.
Urology 2004;63(4):716-21.
2004: Howard I Scher; Mario A Eisenberger; Anthony V D'Amico; Susan Halabi; Eric J Small; Michael J Morris; Michael W Kattan; Mack Roach; Philip W Kantoff; Kenneth J Pienta; Michael A Carducci; David B Agus; Susan F Slovin; Glenn Heller; W Kevin Kelly; Paul H Lange; Daniel P Petrylak; William Berg; Celestia S Higano; George Wilding; Judd W Moul; Alan W Partin; Christopher Logothetis; Howard R Soule
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(3):537-56.
2004: Stephen J Freedland; Alan W Partin
Obesity and prostate cancer detection and progression.
Reviews in urology 2004;6(4):214-6.
2004: Masood A Khan; Alan W Partin
Prostate cancer and chemotherapy.
Reviews in urology 2004;6(3):167-9.
2004: Masood A Khan; Alan W Partin
Finasteride and prostate cancer.
Reviews in urology 2004;6(2):97-8.
2004: Masood A Khan; Alan W Partin
Vitamin d for the management of prostate cancer.
Reviews in urology 2004;6(2):95-7.
2004: Masood A Khan; Alan W Partin
Endothelin-a receptor antagonists and advanced prostate cancer.
Reviews in urology 2004;6(1):47-8.
2004: Masood A Khan; Alan W Partin
Vasectomy and prostate cancer.
Reviews in urology 2004;6(1):46-7.
2004: Masood A Khan; Alan W Partin
Tissue microarrays in prostate cancer research.
Reviews in urology 2004;6(1):44-6.
2004: Robert W Veltri; J Park; M Craig Miller; L Marks; M Kojima; C van Rootselaar; Masood A Khan; Alan W Partin
Stromal-epithelial measurements of prostate cancer in native Japanese and Japanese-American men.
Prostate cancer and prostatic diseases 2004;7(3):232-7.
2004: Misop Han; Alan W Partin; David Y Chan; Patrick C Walsh
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series.
The Journal of urology 2004;171(1):23-6.
2003: Glenn M Cannon; Patrick C Walsh; Alan W Partin; Charles R Pound
Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer.
Urology 2003;62 Suppl 1():2-8.
2003: Masood A Khan; Patrick C Walsh; M Craig Miller; Wesley D Bales; Jonathan I Epstein; Leslie A Mangold; Alan W Partin; Robert W Veltri
Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy.
Cancer 2003;98(12):2583-91.
2003: Jae Park; Lori J Sokoll; Debra J Bruzek; Leslie A Mangold; Robin Gurganus; Masood A Khan; Alan W Partin; Daniel W Chan; Robert W Veltri
Comparison of total prostate-specific antigen and derivative levels in a screening population of black, white, and Korean-American men.
Clinical prostate cancer 2003;2(3):173-6.
2003: Yoshio Naya; Herbert A Fritsche; Carol D Cheli; Thomas A Stamey; Georg Bartsch; Michael K Brawer; Stacy Childs; Samir S Taneja; Herbert Lepor; Alan W Partin; Lori J Sokoll; Daniel W Chan; R Joseph Babaian
Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer.
Urology 2003;62(6):1058-62.
2003: Masood A Khan; H Ballentine Carter; Jonathan I Epstein; M Craig Miller; Patricia Landis; Patrick C Walsh; Alan W Partin; Robert W Veltri
Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?
The Journal of urology 2003;170(6 Pt 1):2274-8.
2003: Susan V Harden; Harriette Sanderson; Steven Goodman; Alan W Partin; Patrick C Walsh; Jonathan I Epstein; David Sidransky
Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies.
Journal of the National Cancer Institute 2003;95(21):1634-7.
2003: Matthew B Gretzer; Alan W Partin
PSA markers in prostate cancer detection.
The Urologic clinics of North America 2003;30(4):677-86.
2003: Masood A Khan; Alan W Partin; Leslie A Mangold; Jonathan I Epstein; Patrick C Walsh
Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer.
Urology 2003;62(5):866-71.
2003: Masood A Khan; Alan W Partin; H Ballentine Carter
Expectant management of localized prostate cancer.
Urology 2003;62(5):793-9.
2003: Kerri Bouwman; Ji Qiu; Heping Zhou; Mark Schotanus; Leslie A Mangold; Robert Vogt; Erik Erlandson; John Trenkle; Alan W Partin; David E Misek; Gilbert S Omenn; Brian B Haab; Samir Hanash
Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity.
Proteomics 2003;3(11):2200-7.
2003: Pankaj Kalra; Joanna Togami; Gaurav Bansal B S; Alan W Partin; Michael K Brawer; Richard J Babaian; Lawrence S Ross; Craig S Niederberger
A neurocomputational model for prostate carcinoma detection.
Cancer 2003;98(9):1849-54.
2003: Alan W Partin; Michael K Brawer; Georg Bartsch; Wolfgang Horninger; Samir S Taneja; Herbert Lepor; R Joseph Babaian; Stacy J Childs; Thomas A Stamey; Herbert A Fritsche; Lori J Sokoll; Daniel W Chan; Robert P Thiel; Carol D Cheli
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
The Journal of urology 2003;170(5):1787-91.
2003: Masood A Khan; Michael A Carducci; Alan W Partin
The evolving role of docetaxel in the management of androgen independent prostate cancer.
The Journal of urology 2003;170(5):1709-16.
2003: Masood A Khan; Alan W Partin; Harry G Rittenhouse; Stephen D Mikolajczyk; Lori J Sokoll; Daniel W Chan; Robert W Veltri
Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
The Journal of urology 2003;170(3):723-6.
2003: Theresa Y Chan; Stephen D Mikolajczyk; Kristin Lecksell; Matthew J Shue; Harry G Rittenhouse; Alan W Partin; Jonathan I Epstein
Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen.
Urology 2003;62(1):177-81.
2003: Masood A Khan; Misop Han; Alan W Partin; Jonathan I Epstein; Patrick C Walsh
Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003.
Urology 2003;62(1):86-91; discussion 91-2.
2003: Masood A Khan; Alan W Partin
Partin tables: past and present.
BJU international 2003;92(1):7-11.
2003: John J Hlavaty; Alan W Partin; Matthew J Shue; Leslie A Mangold; Jennifer Derby; Teofilo Javier; Shane Kelley; Adam Stieg; Joseph V Briggman; G Michael Hass; Ying-Jye Wu
Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer.
Urology 2003;61(6):1261-5.
2003: Alexander Haese; Ville Vaisanen; Judith A Finlay; Kim Pettersson; Harry G Rittenhouse; Alan W Partin; Debra J Bruzek; Lori J Sokoll; Hans Lilja; Daniel W Chan
Standardization of two immunoassays for human glandular kallikrein 2.
Clinical chemistry 2003;49(4):601-10.
2003: Alexander Haese; Manisha Chaudhari; M Craig Miller; Jonathan I Epstein; Hartwig Huland; Jüri Palisaar; Markus Graefen; Peter Hammerer; Edward C Poole; Gerard J O'Dowd; Alan W Partin; Robert W Veltri
Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma: a multiinstitutional validation study.
Cancer 2003;97(4):969-78.
2003: Lori J Sokoll; Daniel W Chan; Stephen D Mikolajczyk; Harry G Rittenhouse; Cindy L Evans; Harry J Linton; Leslie A Mangold; Phaedre Mohr; Georg Bartsch; Helmut Klocker; Wolfgang Horninger; Alan W Partin
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis.
Urology 2003;61(2):274-6.
2003: Misop Han; Alan W Partin; Marianna Zahurak; Steven Piantadosi; Jonathan I Epstein; Patrick C Walsh
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
The Journal of urology 2003;169(2):517-23.
2003: Richard J Babaian; Alan W Partin
Prostate cancer early detection clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2003;1 Suppl 1():S42-55.
2003: Masood A Khan; Alan W Partin
Expectant management of prostate cancer.
Reviews in urology 2003;5(4):247-50.
2003: Masood A Khan; Alan W Partin
Bisphosphonates in metastatic prostate cancer.
Reviews in urology 2003;5(3):204-6.
2003: Matthew B Gretzer; Alan W Partin
Advances in prostate cancer treatment: highlights from the 2nd international prostate cancer congress, st. Thomas, u.s. Virgin islands, july 17-20, 2002.
Reviews in urology 2003;5(2):111-7.
2003: Matthew B Gretzer; Alan W Partin; Daniel W Chan; Robert W Veltri
Modern Tumor Marker Discovery in Urology: Surface Enhanced Laser Desorption and Ionization (SELDI).
Reviews in urology 2003;5(2):81-9.
2003: Masood A Khan; Alan W Partin
Chemoprevention and prostate cancer.
Reviews in urology 2003;5(1):61-3.
2003: Matthew B Gretzer; Alan W Partin
54-year-old male with high-grade prostatic intraepithelial neoplasia on prostate biopsy.
Reviews in urology 2003;5(1):45-8.
2003: Masood A Khan; Alan W Partin
Management of high-risk populations with locally advanced prostate cancer.
The oncologist 2003;8(3):259-69.
2002: Elisabeth Iljas Heath; Theodore L DeWeese; Alan W Partin; Angelo M DeMarzo; John Groopman; William G Nelson; Steven Piantadosi; Ron Lieberman; Michael A Carducci
The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate.
Clinical prostate cancer 2002;1(3):182-7.
2002: Matthew B Gretzer; Jonathan I Epstein; Charles R Pound; Patrick C Walsh; Alan W Partin
Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence.
Urology 2002;60(6):1034-9.
2002: Robert W Veltri; Leonard S Marks; M Craig Miller; Wesley D Bales; John Fan; Maria Luz Macairan; Jonathan I Epstein; Alan W Partin
Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism.
Urology 2002;60(4):617-22.
2002: Robert W Veltri; M Craig Miller; Gerard J O'Dowd; Alan W Partin
Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer.
Urology 2002;60(4 Suppl 1):47-52.
2002: Lars M Ellison; Carol D Cheli; Steven Bright; Robert W Veltri; Alan W Partin
Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening.
Urology 2002;60(4 Suppl 1):42-6.
2002: Yoshio Naya; Thomas A Stamey; Carol D Cheli; Alan W Partin; Lori J Sokoll; Daniel W Chan; Michael K Brawer; Samir S Taneja; Herbert Lepor; Georg Bartsch; Stacy Childs; Herbert A Fritsche; R Joseph Babaian
Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?
Urology 2002;60(4 Suppl 1):36-41.
2002: Wolfgang Horninger; Carol D Cheli; R Joseph Babaian; Herbert A Fritsche; Herbert Lepor; Samir S Taneja; Stacy Childs; Thomas A Stamey; Lori J Sokoll; Daniel W Chan; Michael K Brawer; Alan W Partin; Georg Bartsch
Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
Urology 2002;60(4 Suppl 1):31-5.
2002: Lori J Sokoll; Debra J Bruzek; Renu Dua; Willard Dunn; Phaedre Mohr; Gail Wallerson; Mario A Eisenberger; Alan W Partin; Daniel W Chan
Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen.
Urology 2002;60(4 Suppl 1):24-30.
2002: Lori J Sokoll; Leslie A Mangold; Alan W Partin; Jonathan I Epstein; Debra J Bruzek; Willard Dunn; Phaedre Mohr; Gail Wallerson; Daniel W Chan
Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men.
Urology 2002;60(4 Suppl 1):18-23.
2002: Samir S Taneja; Elias I Hsu; Carol D Cheli; Paul D Walden; Georg Bartsch; Wolfgang Horninger; R Joseph Babaian; Herbert A Fritsche; Stacy Childs; Thomas A Stamey; Lori J Sokoll; Daniel W Chan; Michael K Brawer; Alan W Partin; Herbert Lepor
Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis.
Urology 2002;60(4 Suppl 1):10-7.
2002: Robert W Veltri; Manisha Chaudhari; M Craig Miller; Edward C Poole; Gerard J O'Dowd; Alan W Partin
Comparison of logistic regression and neural net modeling for prediction of prostate cancer pathologic stage.
Clinical chemistry 2002;48(10):1828-34.
2002: Jianfeng Xu; S Lilly Zheng; Akira Komiya; Josyf C Mychaleckyj; Sarah D Isaacs; Jennifer Hu; David Sterling; Ethan M Lange; Gregory A Hawkins; Aubrey Turner; Charles M Ewing; Dennis A Faith; Jill R Johnson; Hiroyoshi Suzuki; Piroska Bujnovszky; Kathleen E Wiley; Angelo M DeMarzo; G Steven Bova; Baoli Chang; M Craig Hall; David L McCullough; Alan W Partin; Vahan S Kassabian; John D Carpten; Joan E Bailey-Wilson; Jeffrey M. Trent; Jill Ohar; Eugene R Bleecker; Patrick C Walsh; William B Isaacs; Deborah A Meyers
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk.
Nature genetics 2002;32(2):321-5.
2002: Alan W Partin; Gerald E Hanks; Eric A Klein; Judd W Moul; William G Nelson; Howard I Scher
Prostate-specific antigen as a marker of disease activity in prostate cancer.
Oncology (Williston Park, N.Y.) 2002;16(9):1218-24; discussion 1224, 1227-8 passim.
2002: Alexander Haese; Jonathan I Epstein; Hartwig Huland; Alan W Partin
Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma.
Cancer 2002;95(5):1016-21.
2002: Michael P Viglione; Stephen Potter; Alan W Partin; Lesniak Maciej; Jonathan I Epstein
Should the diagnosis of benign prostatic hyperplasia be made on prostate needle biopsy?
Human pathology 2002;33(8):796-800.
2002: Alan W Partin; Gerald E Hanks; Eric A Klein; Judd W Moul; William G Nelson; Howard I Scher
Prostate-specific antigen as a marker of disease activity in prostate cancer.
Oncology (Williston Park, N.Y.) 2002;16(8):1024-38, 1042; discussion 1042, 1047-8, 1051.
2002: Alexander Haese; Robert T Dworschack; Alan W Partin
Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
The Journal of urology 2002;168(2):504-8.
2002: Robert W Veltri; M Craig Miller; Leslie A Mangold; Gerard J O'Dowd; Jonathan I Epstein; Alan W Partin
Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
The Journal of urology 2002;168(1):100-4.
2002: Stephen D Mikolajczyk; Leonard S Marks; Alan W Partin; Harry G Rittenhouse
Free prostate-specific antigen in serum is becoming more complex.
Urology 2002;59(6):797-802.
2002: Alexander Haese; Robert T Dworschack; Steven Piccoli; Lori J Sokoll; Alan W Partin; Daniel W Chan
Clinical evaluation of the Elecsys total prostate-specific antigen assay on the Elecsys 1010 and 2010 systems.
Clinical chemistry 2002;48(6 Pt 1):944-7.
2002: EDWARD WRIGHT; Junyong Fang; E Jeffrey Metter; Alan W Partin; Patricia Landis; Daniel W Chan; H Ballentine Carter
Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging.
The Journal of urology 2002;167(6):2484-7; discussion 2487-8.
2002: Danil V Makarov; Harriete Sanderson; Alan W Partin; Jonathan I Epstein
Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
The Journal of urology 2002;167(6):2440-2.
2002: Misop Han; Alan W Partin
Nomograms for clinically localized prostate cancer. Part I: radical prostatectomy.
Seminars in urologic oncology 2002;20(2):123-30.
2002: Koji Okihara; Carol D Cheli; Alan W Partin; Herbert A Fritche; Daniel W Chan; Lori J Sokoll; Michael K Brawer; Morton K Schwartz; Robert L Vessella; Kevin R Loughlin; Dennis A Johnston; R Joseph Babaian
Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.
The Journal of urology 2002;167(5):2017-23; discussion 2023-4.
2002: Ganesh V Raj; Alan W Partin; Thomas J Polascik
Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Cancer 2002;94(4):987-96.
2002: Masood A Khan; Alan W Partin
Evolving Role of Pro-PSA as a New Serum Marker for the Early Detection of Prostate Cancer.
Reviews in urology 2002;4(4):198-200.
2002: Alan W Partin
High-grade prostatic intraepithelial neoplasia on a prostate biopsy-what does it mean?
Reviews in urology 2002;4(3):157-8.
2002: Hans-Joerg Sommerfeld; Alan W Partin; Jürgen Pannek
Incidence of neuroendocrine cells in the seminal vesicles and the prostate--an immunohistochemical study.
International urology and nephrology 2002;34(3):357-60.
2002: Kiaran J O'Malley; Charles R Pound; Patrick C Walsh; Jonathan I Epstein; Alan W Partin
Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy.
Urology 2002;59(1):85-90.
2001: Alan W Partin; Leslie A Mangold; D M Lamm; Patrick C Walsh; Jonathan I Epstein; Jay D Pearson
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.
Urology 2001;58(6):843-8.
2001: D A Barocas; Misop Han; Jonathan I Epstein; David Y Chan; Bruce J Trock; Patrick C Walsh; Alan W Partin
Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?
Urology 2001;58(5):746-51.
2001: Alan W Partin
Letter from the editor.
Urology 2001;58(3):307-9.
2001: Erik T Goluboff; D Prager; D Rukstalis; B Giantonio; M Madorsky; I Barken; I Bernard Weinstein; Alan W Partin; Carl A Olsson
Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy.
The Journal of urology 2001;166(3):882-6.
2001: Misop Han; Alan W Partin; Charles R Pound; Jonathan I Epstein; Patrick C Walsh
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.
The Urologic clinics of North America 2001;28(3):555-65.
2001: M R Feneley; Alan W Partin
Indicators of pathologic stage of prostate cancer and their use in clinical practice.
The Urologic clinics of North America 2001;28(3):443-58.
2001: Misop Han; Alan W Partin; Steven Piantadosi; Jonathan I Epstein; Patrick C Walsh
Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer.
The Journal of urology 2001;166(2):416-9.
2001: Robert W Veltri; M Craig Miller; Alan W Partin; Edward C Poole; Gerard J O'Dowd
Prediction of prostate carcinoma stage by quantitative biopsy pathology.
Cancer 2001;91(12):2322-8.
2001: M Craig Miller; Gerard J O'Dowd; Alan W Partin; Robert W Veltri
Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
Urology 2001;57(6):1105-11.
2001: Steven R Potter; W Horniger; M Tinzl; G Bartsch; Alan W Partin
Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer.
Urology 2001;57(6):1100-4.
2001: William W Roberts; E J Bergstralh; M L Blute; J M Slezak; Michael A Carducci; Misop Han; Jonathan I Epstein; Mario A Eisenberger; Patrick C Walsh; Alan W Partin
Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy.
Urology 2001;57(6):1033-7.
2001: Wolfgang Horninger; Georg Bartsch; PB Snow; JM Brandt; Alan W Partin
The problem of cutoff levels in a screened population: appropriateness of informing screenees about their risk of having prostate carcinoma.
Cancer 2001;91(8 Suppl):1667-72.
2001: Misop Han; PB Snow; JM Brandt; Alan W Partin
Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma.
Cancer 2001;91(8 Suppl):1661-6.
2001: Misop Han; Steven Piantadosi; Marianna Zahurak; Lori J Sokoll; Daniel W Chan; Jonathan I Epstein; Patrick C Walsh; Alan W Partin
Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer.
Urology 2001;57(4):707-11.
2001: Leonard S Marks; Jonathan I Epstein; Alan W Partin
The role of prostate needle biopsy in evaluation of chemopreventive agents.
Urology 2001;57(4 Suppl 1):191-3.
2001: Alan W Partin; L S Marks
Prostate-specific antigen and new serum biomarkers for evaluation of chemopreventive agents.
Urology 2001;57(4 Suppl 1):132-6.
2001: Wael A Sakr; Alan W Partin
Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia.
Urology 2001;57(4 Suppl 1):115-20.
2001: R Lieberman; William G Nelson; Wael A Sakr; F L Meyskens; E A Klein; G Wilding; Alan W Partin; J J Lee; S M Lippman
Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Urology 2001;57(4 Suppl 1):4-27.
2001: JT Batuello; Eduard J Gamito; E David Crawford; Misop Han; Alan W Partin; D G McLeod; C ODonnell
Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer.
Urology 2001;57(3):481-5.
2001: Misop Han; Charles R Pound; Steven R Potter; Alan W Partin; Jonathan I Epstein; Patrick C Walsh
Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications.
The Journal of urology 2001;165(3):864-6.
2001: J Pannek; K L Lecksell; Alan W Partin
Expression of metallothionein in seminal vesicles--an immunohistochemical study.
Scandinavian journal of urology and nephrology 2001;35(1):11-4.
2001: Misop Han; Alan W Partin
Current Clinical Applications of the In-capromab Pendetide Scan (ProstaScint(R) Scan, Cyt-356).
Reviews in urology 2001;3(4):165-71.
2001: Alan W Partin
Cyclooxygenase-2 as a marker for prostate cancer.
Reviews in urology 2001;3(2):107-8.
2001: C R Pound; M K Brawer; Alan W Partin
Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer.
Reviews in urology 2001;3(2):72-84.
2000: Misop Han; P B Snow; Jonathan I Epstein; Theresa Y Chan; K A Jones; Patrick C Walsh; Alan W Partin
A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors after radical prostatectomy.
Urology 2000;56(6):994-9.
2000: Steven R Potter; Leslie A Mangold; Matthew J Shue; D C Taylor; Kristin Lecksell; Jonathan I Epstein; Patrick C Walsh; Alan W Partin
Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy.
Cancer 2000;89(12):2577-86.
2000: Alan W Partin
Does sextant prostate biopsy provide adequate sampling for early detection of prostate cancer?
Current urology reports 2000;1(4):245.
2000: I Simon; P B Snow; L S Marks; W A Christens-Barry; Jonathan I Epstein; David A Bluemke; Alan W Partin
Neural network prediction of prostate tissue composition based on magnetic resonance imaging analysis. A pilot study.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 2000;22(6):445-52.
2000: Theresa Y Chan; Alan W Partin; Patrick C Walsh; Jonathan I Epstein
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy.
Urology 2000;56(5):823-7.
2000: Michael L Blute; E J Bergstralh; Alan W Partin; Patrick C Walsh; Michael W Kattan; Peter T Scardino; James E Montie; Jay D Pearson; J M Slezak; Horst Zincke
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer.
The Journal of urology 2000;164(5):1591-5.
2000: D G Smith; S R Potter; B R Lee; H W Ko; W R Drummond; J K Telford; Alan W Partin
In vivo measurement of tumor conductiveness with the magnetic bioimpedance method.
IEEE transactions on bio-medical engineering 2000;47(10):1403-5.
2000: Jonathan I Epstein; Alan W Partin; Steven R Potter; Patrick C Walsh
Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters.
Urology 2000;56(2):283-8.
2000: William J Catalona; PC Southwick; Kevin Slawin; Alan W Partin; Michael K Brawer; RC Flanigan; A Patel; JP Richie; Patrick C Walsh; Peter T Scardino; PH Lange; GH Gasior; KG Loveland; KR Bray
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.
Urology 2000;56(2):255-60.
2000: M R Feneley; Alan W Partin
Diagnosis of localized prostate cancer: 10 years of progress.
Current opinion in urology 2000;10(4):319-27.
2000: Misop Han; Patrick C Walsh; Alan W Partin; Ronald Rodriguez
Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease.
The Journal of urology 2000;164(1):89-92.
2000: ZP Wang; Mario A Eisenberger; Michael A Carducci; Alan W Partin; Howard I Scher; PO Ts'o
Identification and characterization of circulating prostate carcinoma cells.
Cancer 2000;88(12):2787-95.
2000: T Reckwitz; Steven R Potter; Alan W Partin
Prediction of locoregional extension and metastatic disease in prostate cancer: a review.
World journal of urology 2000;18(3):165-72.
2000: Robert L Vessella; P H Lange; Alan W Partin; Daniel W Chan; Lori J Sokoll; E A Sasse; E D Crawford
Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays.
Urology 2000;55(6):909-14.
2000: Edward G Weir; Alan W Partin; Jonathan I Epstein
Correlation of serum prostate specific antigen and quantitative immunohistochemistry.
The Journal of urology 2000;163(6):1739-42.
2000: Misop Han; Steven R Potter; Alan W Partin
The role of free prostate-specific antigen in prostate cancer detection.
Current urology reports 2000;1(1):78-82.
2000: C R Pound; Alan W Partin
What does prostate-specific antigen recurrence mean?
Current urology reports 2000;1(1):28-35.
2000: MARY RIPPLE; S R Potter; Alan W Partin; Jonathan I Epstein
Needle biopsy of recurrent adenocarcinoma of the prostate after radical prostatectomy.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2000;13(5):521-7.
2000: E David Crawford; JT Batuello; P Snow; Eduard J Gamito; D G McLeod; Alan W Partin; N Stone; James E Montie; Richard Stock; J Lynch; J Brandt
The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma.
Cancer 2000;88(9):2105-9.
2000: Michael K Brawer; Carol D Cheli; IE Neaman; J Goldblatt; C Smith; Morton K Schwartz; Debra J Bruzek; D L Morris; Lori J Sokoll; Daniel W Chan; KK Yeung; Alan W Partin; W Jeffrey Allard
Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
The Journal of urology 2000;163(5):1476-80.
2000: Leonard S Marks; Alan W Partin; Jonathan I Epstein; Varro E Tyler; I Simon; Maria Luz Macairan; Theresa Y Chan; Frederick J Dorey; JB Garris; Robert W Veltri; PB Santos; K A Stonebrook; Jean B deKernion
Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia.
The Journal of urology 2000;163(5):1451-6.
2000: C C Pan; Steven R Potter; Alan W Partin; Jonathan I Epstein
The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system.
The American journal of surgical pathology 2000;24(4):563-9.
2000: William J Catalona; Alan W Partin; Kevin Slawin; C K Naughton; Michael K Brawer; RC Flanigan; JP Richie; A Patel; Patrick C Walsh; Peter T Scardino; PH Lange; Jean B deKernion; PC Southwick; KG Loveland; RE Parson; GH Gasior
Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial.
Urology 2000;55(3):372-6.
2000: Alan W Partin; G P Murphy; M K Brawer
Report on Prostate Cancer Tumor Marker Workshop 1999.
Cancer 2000;88(4):955-63.
2000: P LaFontaine; David Y Chan; Alan W Partin; Robin Gurganus; Steven Hortopan; Fray F Marshall
Minilaparotomy radical retropubic prostatectomy: updated technique and results.
Seminars in urologic oncology 2000;18(1):19-27.
2000: S R Potter; Jonathan I Epstein; Alan W Partin
Seminal vesicle invasion by prostate cancer: prognostic significance and therapeutic implications.
Reviews in urology 2000;2(3):190-5.
2000: S R Potter; Alan W Partin
Tumor markers: an update on human kallikrein 2.
Reviews in urology 2000;2(4):221-2.
2000: S R Potter; Alan W Partin
The significance of perineural invasion found on needle biopsy of the prostate: implications for definitive therapy.
Reviews in urology 2000;2(2):87-90.
2000: S R Potter; Alan W Partin
Hereditary and familial prostate cancer: biologic aggressiveness and recurrence.
Reviews in urology 2000;2(1):35-6.
2000: Robert W Veltri; Alan W Partin; M C Miller
Quantitative nuclear grade (QNG): a new image analysis-based biomarker of clinically relevant nuclear structure alterations.
Journal of cellular biochemistry. Supplement 2000;Suppl 35():151-7.
2000: William G Nelson; Jonathan W Simons; Bahar Mikhak; J F Chang; Angelo M DeMarzo; Michael A Carducci; M Kim; CE Weber; AA Baccala; M A Goeman; Shirley Clift; Dale Ando; Hyam I Levitsky; LK Cohen; M G Sanda; Richard C Mulligan; Alan W Partin; H Ballentine Carter; Steven Piantadosi; Fray F Marshall
Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Cancer chemotherapy and pharmacology 2000;46 Suppl():S67-72.
2000: Bob Djavan; Alan W Partin; M F Hoey; Claus G Roehrborn; C M Dixon; Michael Marberger
Transurethral radiofrequency therapy for benign prostatic hyperplasia using a novel saline-liquid conductor: the virtual electrode.
Urology 2000;55(1):13-6.
1999: Mark Hurwitz; Theodore L DeWeese; EVA ZINREICH; Jonathan I Epstein; Alan W Partin
Nuclear morphometry predicts disease-free interval for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy.
International journal of cancer. Journal international du cancer 1999;84(6):594-7.
1999: TJ Wang; Harry J Linton; J Payne; Harry G Rittenhouse; Daniel W Chan; Alan W Partin; RL Wolfert; Kristine Kuus-Reichel
Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay.
Hybridoma 1999;18(6):535-41.
1999: P F Lemkin; J M Myrick; Yegappan Lakshmanan; M J Shue; J L Patrick; Peter Hornbeck; G C Thornwal; Alan W Partin
Exploratory data analysis groupware for qualitative and quantitative electrophoretic gel analysis over the Internet-WebGel.
Electrophoresis 1999;20(18):3492-507.
1999: Michael J Manyak; George Hinkle; Johannes O Olsen; R P Chiaccherini; Alan W Partin; Steven Piantadosi; JK Burgers; JH Texter; Charles E Neal; John A Libertino; G L Wright; RT Maguire
Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer.
Urology 1999;54(6):1058-63.
1999: J Pannek; Yegappan Lakshmanan; Charles R Pound; P F Lemkin; Jonathan I Epstein; Alan W Partin
Nuclear shape and nuclear matrix protein composition in prostate and seminal vesicles.
Urology 1999;54(5):934-9.
1999: Alan W Partin; William J Catalona; Judith A Finlay; Claude Darte; Donald J Tindall; Charles Y F Young; George G Klee; Daniel W Chan; Harry G Rittenhouse; RL Wolfert; David L Woodrum
Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis.
Urology 1999;54(5):839-45.
1999: Steven R Potter; M Craig Miller; Leslie A Mangold; K A Jones; Jonathan I Epstein; Robert W Veltri; Alan W Partin
Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy.
Urology 1999;54(5):791-5.
1999: Jonathan W Simons; Bahar Mikhak; J F Chang; Angelo M DeMarzo; Michael A Carducci; M Lim; CE Weber; AA Baccala; M A Goemann; Shirley Clift; Dale Ando; Hyam I Levitsky; LK Cohen; M G Sanda; Richard C Mulligan; Alan W Partin; H Ballentine Carter; Steven Piantadosi; Fray F Marshall; William G Nelson
Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
Cancer research 1999;59(20):5160-8.
1999: Steven R Potter; Alan W Partin
Prostate cancer: detection, staging, and treatment of localized disease.
Seminars in roentgenology 1999;34(4):269-83.
1999: Steven R Potter; Alan W Partin
Prostatitis syndromes and benign prostatic hyperplasia.
Seminars in roentgenology 1999;34(4):256-68.
1999: PC Southwick; William J Catalona; Alan W Partin; Kevin Slawin; Michael K Brawer; RC Flanigan; A Patel; JP Richie; Patrick C Walsh; Peter T Scardino; PH Lange; GH Gasior; RE Parson; KG Loveland
Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
The Journal of urology 1999;162(4):1346-51.
1999: CR Pound; O W Christens-Barry; Robin Gurganus; Alan W Partin; Patrick C Walsh
Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy.
The Journal of urology 1999;162(4):1337-40.
1999: TJ Polascik; ZP Wang; M Shue; S Di; Robin Gurganus; Steven Hortopan; PO Ts'o; Alan W Partin
Influence of sextant prostate needle biopsy or surgery on the detection and harvest of intact circulating prostate cancer cells.
The Journal of urology 1999;162(3 Pt 1):749-52.
1999: William J Catalona; Alan W Partin; Judith A Finlay; Daniel W Chan; Harry G Rittenhouse; RL Wolfert; David L Woodrum
Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model.
Urology 1999;54(2):220-4.
1999: TJ Polascik; J E Oesterling; Alan W Partin
Prostate specific antigen: a decade of discovery--what we have learned and where we are going.
The Journal of urology 1999;162(2):293-306.
1999: Norman E Breslow; Alan W Partin; B R Lee; Katherine A Guthrie; J Bruce Beckwith; Daniel M Green
Nuclear morphometry and prognosis in favorable histology Wilms' tumor: A prospective reevaluation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2123-6.
1999: A M Williams; I Simon; Patricia Landis; C Moser; W Christens-Barry; H Ballentine Carter; E Jeffrey Metter; Alan W Partin
Prostatic growth rate determined from MRI data: age-related longitudinal changes.
Journal of andrology 1999;20(4):474-80.
1999: Steven R Potter; T Reckwitz; Alan W Partin
The use of percent free PSA for early detection of prostate cancer.
Journal of andrology 1999;20(4):449-53.
1999: K M Ruska; Alan W Partin; Jonathan I Epstein; H Kahane
Adenocarcinoma of the prostate in men younger than 40 years of age: diagnosis and treatment with emphasis on radical prostatectomy findings.
Urology 1999;53(6):1179-83.
1999: EN Subong; Matthew J Shue; Jonathan I Epstein; Joseph V Briggman; P K Chan; Alan W Partin
Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23.
The Prostate 1999;39(4):298-304.
1999: JK Chon; Andrew Borkowski; Alan W Partin; John T Isaacs; Stephen C Jacobs; Natasha Kyprianou
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
The Journal of urology 1999;161(6):2002-8.
1999: B R Lee; William W Roberts; D G Smith; H W Ko; Jonathan I Epstein; Kristin Lecksell; Alan W Partin
Bioimpedance: novel use of a minimally invasive technique for cancer localization in the intact prostate.
The Prostate 1999;39(3):213-8.
1999: Charles R Pound; Alan W Partin; Mario A Eisenberger; Daniel W Chan; Jay D Pearson; Patrick C Walsh
Natural history of progression after PSA elevation following radical prostatectomy.
JAMA : the journal of the American Medical Association 1999;281(17):1591-7.
1999: Salvatore Micali; RI Silver; Howard S Kaufman; V D Douglas; G M Marley; Alan W Partin; Robert G Moore; Louis R Kavoussi; Steven G Docimo
Measurement of urinary N-acetyl-beta-D-glucosaminidase to assess renal ischemia during laparoscopic operations.
Surgical endoscopy 1999;13(5):503-6.
1999: TJ Polascik; Michael J Manyak; Michael K Haseman; Robin Gurganus; B Rogers; RT Maguire; Alan W Partin
Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.
Cancer 1999;85(7):1586-92.
1999: Leonard S Marks; Alan W Partin; Frederick J Dorey; Gleen J Gormley; Jonathan I Epstein; JB Garris; Maria Luz Macairan; ED Shery; PB Santos; Elizabeth Stoner; Jean B deKernion
Long-term effects of finasteride on prostate tissue composition.
Urology 1999;53(3):574-80.
1999: TJ Polascik; Ulrike M Hamper; B R Lee; Y Dai; John Hilton; Carolyn A Magee; J K Crone; M J Shue; M Ferrell; V Trapanotto; M Adiletta; Alan W Partin
Ablation of renal tumors in a rabbit model with interstitial saline-augmented radiofrequency energy: preliminary report of a new technology.
Urology 1999;53(3):465-72; discussion 470-2.
1999: Bob Djavan; S Shariat; Mitra Fakhari; K Ghawidel; Christian Seitz; Alan W Partin; Claus G Roehrborn; Michael Marberger
Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial.
Urology 1999;53(2):251-9.
1999: S R Potter; Alan W Partin
Prostate biopsy schemes and the detection of prostate cancer.
Reviews in urology 1999;1(4):207-8.
1999: Alan W Partin; B Djavan
BPH Plus Prostate Cancer Therapy and Markers Featured at EAU: Highlights from the 14th Annual Congress of the European Association of Urology April 7-10, 1999, Stockholm, Sweden.
Reviews in urology 1999;1(4):180-92.
1999: S R Potter; Alan W Partin
Urinary incontinence after radical retropubic prostatectomy.
Reviews in urology 1999;1(2):97-8.
1999: Alan W Partin
Prostate Cancer Markers and Treatments Ranging From Gene Therapy to Cryosurgery Examined at AUA: Highlights from the American Urological Association 93rd Annual Meeting May 30-June 4, 1998, San Diego, Calif.
Reviews in urology 1999;1(2):82-91.
1999: Lori J Sokoll; Alan W Partin; J B Nelson; Daniel W Chan
Critical analysis of false elevations in PSA results reported with the Abbott AxSYM assay.
The Prostate 1999;38(1):79-80.
1999: Claus F Eisenberger; Patrick C Walsh; Mario A Eisenberger; N H Chow; Alan W Partin; Jacek L Mostwin; Fray F Marshall; Jonathan I Epstein; Mark P Schoenberg
Incidental non-Hodgkin's lymphoma in patients with localized prostate cancer.
Urology 1999;53(1):175-9.
1999: H Ballentine Carter; Jonathan I Epstein; Alan W Partin
Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease.
Urology 1999;53(1):126-30.
1999: Michael A Carducci; Steven Piantadosi; Charles R Pound; Jonathan I Epstein; J W Simons; Fray F Marshall; Alan W Partin
Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma.
Urology 1999;53(1):44-9.
1998: TJ Polascik; Alan W Partin; Charles R Pound; Fray F Marshall
Frequent occurrence of metastatic disease in patients with renal cell carcinoma and intrahepatic or supradiaphragmatic intracaval extension treated with surgery: an outcome analysis.
Urology 1998;52(6):995-9.
1998: Fray F Marshall; David Y Chan; Alan W Partin; Robin Gurganus; Steven Hortopan
Minilaparotomy radical retropubic prostatectomy: technique and results.
The Journal of urology 1998;160(6 Pt 2):2440-5.
1998: GP Murphy; Alan W Partin
Workshop on Prostate Markers. International Union Against Cancer.
Cancer 1998;83(10):2233-8.
1998: Alan W Partin; R E Stutzman
Elevated prostate-specific antigen, abnormal prostate evaluation on digital rectal examination, and transrectal ultrasound and prostate biopsy.
The Urologic clinics of North America 1998;25(4):581-9, viii.
1998: GD Carlson; CB Calvanese; Alan W Partin
An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases.
Urology 1998;52(3):455-61.
1998: G Steven Bova; Alan W Partin; Sarah D Isaacs; B S Carter; Terri H beaty; William B Isaacs; Patrick C Walsh
Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy.
The Journal of urology 1998;160(3 Pt 1):660-3.
1998: Harry G Rittenhouse; Judith A Finlay; Stephen D Mikolajczyk; Alan W Partin
Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate.
Critical reviews in clinical laboratory sciences 1998;35(4):275-368.
1998: T J Polascik; Jay D Pearson; Alan W Partin
Multivariate models as predictors of pathological stage using Gleason score, clinical stage, and serum prostate-specific antigen.
Seminars in urologic oncology 1998;16(3):160-71.
1998: J Pannek; Alan W Partin
The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer.
Seminars in urologic oncology 1998;16(3):100-5.
1998: L R Miller; Alan W Partin; Daniel W Chan; Debra J Bruzek; Adrian S Dobs; Jonathan I Epstein; Patrick C Walsh
Influence of radical prostatectomy on serum hormone levels.
The Journal of urology 1998;160(2):449-53.
1998: Jonathan I Epstein; Charles R Pound; Alan W Partin; Patrick C Walsh
Disease progression following radical prostatectomy in men with Gleason score 7 tumor.
The Journal of urology 1998;160(1):97-100; discussion 101.
1998: William J Catalona; Alan W Partin; Kevin Slawin; Michael K Brawer; RC Flanigan; A Patel; JP Richie; Jean B deKernion; Patrick C Walsh; Peter T Scardino; PH Lange; EN Subong; RE Parson; GH Gasior; KG Loveland; PC Southwick
Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.
JAMA : the journal of the American Medical Association 1998;279(19):1542-7.
1998: B R Lee; R I Silver; Alan W Partin; Jonathan I Epstein; John P Gearhart
A quantitative histologic analysis of collagen subtypes: the primary obstructed and refluxing megaureter of childhood.
Urology 1998;51(5):820-3.
1998: M L Wills; Jurga Sauvageot; Alan W Partin; Robin Gurganus; Jonathan I Epstein
Ability of sextant biopsies to predict radical prostatectomy stage.
Urology 1998;51(5):759-64.
1998: I Simon; CR Pound; Alan W Partin; J Quentin Clemens; W A Christens-Barry
Automated image analysis system for detecting boundaries of live prostate cancer cells.
Cytometry 1998;31(4):287-94.
1998: Yegappan Lakshmanan; EN Subong; Alan W Partin
Differential nuclear matrix protein expression in prostate cancers: correlation with pathologic stage.
The Journal of urology 1998;159(4):1354-8.
1998: J Pannek; Harry G Rittenhouse; Daniel W Chan; Jonathan I Epstein; Patrick C Walsh; Alan W Partin
The use of percent free prostate specific antigen for staging clinically localized prostate cancer.
The Journal of urology 1998;159(4):1238-42.
1998: J Pannek; Leonard S Marks; Jay D Pearson; Harry G Rittenhouse; Daniel W Chan; ED Shery; Gleen J Gormley; EN Subong; C A Kelley; Elizabeth Stoner; Alan W Partin
Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia.
The Journal of urology 1998;159(2):449-53.
1998: B R Lee; J A Caddedu; G Janetschek; Peter Schulam; Steven G Docimo; Robert G Moore; Alan W Partin; Louis R Kavoussi
International surgical telementoring: our initial experience.
Studies in health technology and informatics 1998;50():41-7.
1998: Jeffrey A Cadeddu; Alan W Partin; Theodore L DeWeese; Patrick C Walsh
Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy.
The Journal of urology 1998;159(1):173-7; discussion 177-8.
1998: DL Woodrum; Michael K Brawer; Alan W Partin; William J Catalona; PC Southwick
Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.
The Journal of urology 1998;159(1):5-12.
1997: GP Murphy; R T Maguire; B Rogers; Alan W Partin; W B Nelp; MJ Troychak; Haakon Ragde; GM Kenny; RJ Barren; VA Bowes; AK Gregorakis; Eric H Holmes; AL Boynton
Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients.
The Prostate 1997;33(4):281-5.
1997: William F Page; M M Braun; Alan W Partin; N Caporaso; Patrick C Walsh
Heredity and prostate cancer: a study of World War II veteran twins.
The Prostate 1997;33(4):240-5.
1997: Alan W Partin; Joseph V Briggman; EN Subong; R Szaro; A Oreper; S Wiesbrock; J Meyer; Donald S Coffey; Jonathan I Epstein
Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins.
Urology 1997;50(5):800-8.
1997: J Pannek; Harry G Rittenhouse; Cindy L Evans; Judith A Finlay; Debra J Bruzek; J L Cox; Daniel W Chan; EN Subong; Alan W Partin
Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer.
Urology 1997;50(5):715-21.
1997: Patrick C Walsh; Alan W Partin
Family history facilitates the early diagnosis of prostate carcinoma.
Cancer 1997;80(9):1871-4.
1997: J Pannek; Alan W Partin
Prostate-specific antigen: what's new in 1997.
Oncology (Williston Park, N.Y.) 1997;11(9):1273-8; discussion 1279-82.
1997: Jeffrey A Cadeddu; Alan W Partin; Jonathan I Epstein; Patrick C Walsh
Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy.
Urology 1997;50(2):251-5.
1997: PO Ts'o; J Pannek; ZP Wang; stephen lesko; G Steven Bova; Alan W Partin
Detection of intact prostate cancer cells in the blood of men with prostate cancer.
Urology 1997;49(6):881-5.
1997: Leonard S Marks; Alan W Partin; Gleen J Gormley; Frederick J Dorey; ED Shery; JB Garris; EN Subong; Elizabeth Stoner; Jean B deKernion
Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.
The Journal of urology 1997;157(6):2171-8.
1997: Alan W Partin; Michael W Kattan; EN Subong; Patrick C Walsh; Kirk J Wojno; JE Oesterling; Peter T Scardino; Jay D Pearson
Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
JAMA : the journal of the American Medical Association 1997;277(18):1445-51.
1997: Charles R Pound; Alan W Partin; Jonathan I Epstein; Patrick C Walsh
Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.
The Urologic clinics of North America 1997;24(2):395-406.
1997: H Ballentine Carter; Alan W Partin; A A Luderer; E Jeffrey Metter; Patricia Landis; Daniel W Chan; J L Fozard; Jay D Pearson
Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis.
Urology 1997;49(3):379-84.
1997: M L Wills; Ulrike M Hamper; Alan W Partin; Jonathan I Epstein
Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens.
Urology 1997;49(3):367-73.
1997: Martin G Sanda; C B Doehring; Bruce Binkowitz; Terri H beaty; Alan W Partin; E Hale; Elizabeth Stoner; Patrick C Walsh
Clinical and biological characteristics of familial benign prostatic hyperplasia.
The Journal of urology 1997;157(3):876-9.
1997: MA Silberman; Alan W Partin; Robert W Veltri; Jonathan I Epstein
Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate.
Cancer 1997;79(4):772-9.
1997: RI Silver; Alan W Partin; Jonathan I Epstein; Daniel W Chan; H Ballentine Carter; RD Jeffs; John P Gearhart
Prostate-specific antigen in men born with bladder exstrophy.
Urology 1997;49(2):253-6.
1997: Charles R Pound; Patrick C Walsh; Jonathan I Epstein; Daniel W Chan; Alan W Partin
Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer.
World journal of urology 1997;15(6):373-7.
1996: Alan W Partin; William J Catalona; PC Southwick; EN Subong; GH Gasior; Daniel W Chan
Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age.
Urology 1996;48(6A Suppl):55-61.
1996: J Pannek; EN Subong; K A Jones; P L Marschke; Jonathan I Epstein; Daniel W Chan; H Ballentine Carter; A A Luderer; Alan W Partin
The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer.
Urology 1996;48(6A Suppl):51-4.
1996: R P Thiel; J E Oesterling; K J Wojno; Alan W Partin; Daniel W Chan; H Ballentine Carter; T A Stamey; A R Prestigiacomo; Michael K Brawer; J C Petteway; G Carlson; A A Luderer
Multicenter comparison of the diagnostic performance of free prostate-specific antigen.
Urology 1996;48(6A Suppl):45-50.
1996: Jay D Pearson; A A Luderer; E Jeffrey Metter; Alan W Partin; Daniel W Chan; JL Fozard; H Ballentine Carter
Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer.
Urology 1996;48(6A Suppl):4-9.
1996: Alan W Partin; J E Oesterling
The clinical usefulness of percent free-PSA.
Urology 1996;48(6A Suppl):1-3.
1996: B R Lee; Elizabeth J. Perlman; Alan W Partin; RD Jeffs; John P Gearhart
Evaluation of smooth muscle and collagen subtypes in normal newborns and those with bladder exstrophy.
The Journal of urology 1996;156(6):2034-6.
1996: Alan W Partin; H Ballentine Carter
The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer.
The Urologic clinics of North America 1996;23(4):531-40.
1996: Robert W Veltri; M C Miller; Alan W Partin; Donald S Coffey; Jonathan I Epstein
Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei.
Urology 1996;48(5):685-91.
1996: C B Doehring; Martin G Sanda; Alan W Partin; Jurga Sauvageot; H Juo; Terri H beaty; Jonathan I Epstein; G Hill; Patrick C Walsh
Histopathologic characterization of hereditary benign prostatic hyperplasia.
Urology 1996;48(4):650-3.
1996: Leonard S Marks; Frederick J Dorey; T Rhodes; E D Shery; Harry G Rittenhouse; Alan W Partin; Jean B deKernion
Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia.
The Journal of urology 1996;156(3):1035-9.
1996: R C Smith; Alan W Partin; Jonathan I Epstein; Charles B Brendler
Extended followup of the influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer and extensive capsular perforation.
The Journal of urology 1996;156(2 Pt 1):454-7; discussion 457-8.
1996: M H Weinstein; Alan W Partin; Robert W Veltri; Jonathan I Epstein
Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy.
Human pathology 1996;27(7):683-7.
1996: T Niesel; Alan W Partin; Patrick C Walsh
Anatomic approach for placement of surgical drains after radical retropubic prostatectomy: long-term effects on postoperative pain.
Urology 1996;48(1):91-4.
1996: Alan W Partin; S R Criley; EN Subong; H Zincke; Patrick C Walsh; J E Oesterling
Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.
The Journal of urology 1996;155(4):1336-9.
1996: Jonathan I Epstein; Alan W Partin; Jurga Sauvageot; Patrick C Walsh
Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up.
The American journal of surgical pathology 1996;20(3):286-92.
1996: R G Moore; Alan W Partin; L R Kavoussi
Role of laparoscopy in the diagnosis and treatment of prostate cancer.
Seminars in surgical oncology 1996;12(2):139-44.
1996: Robert G Moore; J B Adams; Alan W Partin; Steven G Docimo; Louis R Kavoussi
Telementoring of laparoscopic procedures: initial clinical experience.
Surgical endoscopy 1996;10(2):107-10.
1996: Alan W Partin
Prostate cancer--educating ourselves and our nonurological colleagues.
The Journal of urology 1996;155(2):610-1.
1996: Alan W Partin; Steven Piantadosi; EN Subong; C A Kelly; S Hortopan; Daniel W Chan; RL Wolfert; Harry G Rittenhouse; H Ballentine Carter
Clearance rate of serum-free and total PSA following radical retropubic prostatectomy.
The Prostate. Supplement 1996;7():35-9.
1996: J Ben-Chaim; Alan W Partin; RD Jeffs
Ureteral bladder augmentation using the lower pole ureter of a duplicated system.
Urology 1996;47(1):135-7.
1995: Alan W Partin; J B Adams; Robert G Moore; Louis R Kavoussi
Complete robot-assisted laparoscopic urologic surgery: a preliminary report.
Journal of the American College of Surgeons 1995;181(6):552-7.
1995: Louis R Kavoussi; Robert G Moore; J B Adams; Alan W Partin
Comparison of robotic versus human laparoscopic camera control .
The Journal of urology 1995;154(6):2134-6.
1995: TJ Polascik; Charles R Pound; M V Meng; Alan W Partin; Fray F Marshall
Partial nephrectomy: technique, complications and pathological findings.
The Journal of urology 1995;154(4):1312-8.
1995: D M Quinlan; Alan W Partin; Patrick C Walsh
Can aggressive prostatic carcinomas be identified and can their natural history be altered by treatment?
Urology 1995;46(3 Suppl A):77-82.
1995: J B Adams; Peter Schulam; Robert G Moore; Alan W Partin; Louis R Kavoussi
New laparoscopic suturing device: initial clinical experience.
Urology 1995;46(2):242-5.
1995: Robert G Moore; Alan W Partin; J B Adams; Louis R Kavoussi
Adhesion formation after transperitoneal nephrectomy: laparoscopic v open approach.
Journal of endourology / Endourological Society 1995;9(3):277-80.
1995: Alan W Partin; Steven Piantadosi; Martin G Sanda; Jonathan I Epstein; Fray F Marshall; James L Mohler; Charles B Brendler; Patrick C Walsh; Jonathan W Simons
Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy.
Urology 1995;45(5):831-8.
1995: Jeffrey A Cadeddu; Jay D Pearson; BR Lee; Patricia Landis; Alan W Partin; Jonathan I Epstein; H Ballentine Carter
Relationship between changes in prostate-specific antigen and the percent of prostatic epithelium in men with benign prostatic hyperplasia.
Urology 1995;45(5):795-800.
1995: Maureen A Riopel; TJ Polascik; Alan W Partin; Jurga Sauvageot; Patrick C Walsh; Jonathan I Epstein
Radical prostatectomy in men less than 50 years old.
Urologic oncology 1995;1(2):80-3.
1995: M J Carmichael; Robert W Veltri; Alan W Partin; M C Miller; Patrick C Walsh; Jonathan I Epstein
Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease.
The Journal of urology 1995;153(3 Pt 2):1015-9.
1995: Alan W Partin; S R Criley; M S Steiner; K Hsieh; Jonathan W Simons; J Lumadue; H Ballentine Carter; Fray F Marshall
Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor volume.
Urology 1995;45(2):211-7.
1995: John P Gearhart; B R Lee; Alan W Partin; Jonathan I Epstein; John A Gosling
A quantitative histological evaluation of the dilated ureter of childhood. II: Ectopia, posterior urethral valves and the prune belly syndrome.
The Journal of urology 1995;153(1):172-6.
1995: Jonathan I Epstein; M Carmichael; Alan W Partin
OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate.
Urology 1995;45(1):81-6.
1995: John P Gearhart; J R Willmann; J B Beckwith; Jonathan I Epstein; Alan W Partin
Nuclear morphometric analysis of metastasis in Wilms' tumor after multimodal therapy: comparison with primary tumor.
Urology 1995;45(1):119-23.
1995: Fray F Marshall; Gary D Steinberg; Charles R Pound; Alan W Partin
Radical surgery for renal-cell carcinoma: caval neoplastic excision, adrenalectomy, lymphadenectomy, adjacent organ resection.
World journal of urology 1995;13(3):159-62.
1994: James L Mohler; W M Figlesthaler; X Z Zhang; Alan W Partin; Susan J Maygarden
Nuclear shape analysis for the assessment of local invasion and metastases in clinically localized prostate carcinoma.
Cancer 1994;74(11):2996-3001.
1994: Carrie W Rinker-Schaeffer; Alan W Partin; William B Isaacs; Donald S Coffey; John T Isaacs
Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells.
The Prostate 1994;25(5):249-65.
1994: Alan W Partin; W F Page; BR Lee; Martin G Sanda; R N Miller; Patrick C Walsh
Concordance rates for benign prostatic disease among twins suggest hereditary influence.
Urology 1994;44(5):646-50.
1994: Patrick C Walsh; Alan W Partin; Jonathan I Epstein
Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years.
The Journal of urology 1994;152(5 Pt 2):1831-6.
1994: Alan W Partin; J E Oesterling
The clinical usefulness of prostate specific antigen: update 1994.
The Journal of urology 1994;152(5 Pt 1):1358-68.
1994: Louis R Kavoussi; Robert G Moore; Alan W Partin; Jeffrey S Bender; Michael E Zenilman; R M Satava
Telerobotic assisted laparoscopic surgery: initial laboratory and clinical experience.
Urology 1994;44(1):15-9.
1994: Alan W Partin; Patrick C Walsh
Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
The Journal of urology 1994;152(1):172-3.
1994: Jonathan I Epstein; M J Carmichael; Alan W Partin; Patrick C Walsh
Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications.
The Journal of urology 1994;151(6):1587-92.
1994: Alan W Partin; B R Lee; M Carmichael; Patrick C Walsh; Jonathan I Epstein
Radical prostatectomy for high grade disease: a reevaluation 1994.
The Journal of urology 1994;151(6):1583-6.
1994: Alan W Partin; Jay D Pearson; Patricia Landis; H Ballentine Carter; Charles R Pound; J Quentin Clemens; Jonathan I Epstein; Patrick C Walsh
Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.
Urology 1994;43(5):649-59.
1994: Alan W Partin; J K Yoo; D Crooks; Jonathan I Epstein; J B Beckwith; John P Gearhart
Prediction of disease-free survival after therapy in Wilms' tumor using nuclear morphometric techniques.
Journal of pediatric surgery 1994;29(3):456-60.
1994: Patrick C Walsh; Alan W Partin
Treatment of early stage prostate cancer: radical prostatectomy.
Important advances in oncology 1994;():211-23.
1994: Robert W Veltri; Alan W Partin; Jonathan I Epstein; G M Marley; C M Miller; D S Singer; K P Patton; S R Criley; Donald S Coffey
Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression.
Journal of cellular biochemistry. Supplement 1994;19():249-58.
1994: Alan W Partin; Donald S Coffey
Benign and malignant prostatic neoplasms: human studies.
Recent progress in hormone research 1994;49():293-331.
1993: Alan W Partin; Charles R Pound; J Quentin Clemens; Jonathan I Epstein; Patrick C Walsh
Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years.
The Urologic clinics of North America 1993;20(4):713-25.
1993: Jeffrey A Cadeddu; Jay D Pearson; Alan W Partin; Jonathan I Epstein; H Ballentine Carter
Relationship between changes in prostate-specific antigen and prognosis of prostate cancer.
Urology 1993;42(4):383-9.
1993: Charles R Pound; Alan W Partin; Jonathan I Epstein; J W Simons; Fray F Marshall
Nuclear morphometry accurately predicts recurrence in clinically localized renal cell carcinoma.
Urology 1993;42(3):243-8.
1993: Alan W Partin; R N Borland; Jonathan I Epstein; Charles B Brendler
Influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer with established capsular penetration.
The Journal of urology 1993;150(1):142-6; discussion 146-8.
1993: Alan W Partin; J Yoo; H Ballentine Carter; Jay D Pearson; Daniel W Chan; Jonathan I Epstein; Patrick C Walsh
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
The Journal of urology 1993;150(1):110-4.
1993: Jonathan I Epstein; M Carmichael; Alan W Partin; Patrick C Walsh
Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup.
The Journal of urology 1993;149(6):1478-81.
1993: D E Epner; Alan W Partin; J A Schalken; John T Isaacs; Donald S Coffey
Association of glyceraldehyde-3-phosphate dehydrogenase expression with cell motility and metastatic potential of rat prostatic adenocarcinoma.
Cancer research 1993;53(9):1995-7.
1993: Alan W Partin; Robert H Getzenberg; M J CarMichael; D Vindivich; J Yoo; Jonathan I Epstein; Donald S Coffey
Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer.
Cancer research 1993;53(4):744-6.
1993: R N Borland; Alan W Partin; Jonathan I Epstein; Charles B Brendler
The use of nuclear morphometry in predicting recurrence of transitional cell carcinoma.
The Journal of urology 1993;149(2):272-5.
1993: Alan W Partin; John P Gearhart; Michael P Leonard; B G Leventhal; J K Yoo; D Crooks; Jonathan I Epstein; J B Beckwith
The use of nuclear morphometry to predict prognosis in pediatric urologic malignancies: a review.
Medical and pediatric oncology 1993;21(3):222-9.
1993: C M Tempany; Alan W Partin; Robert Harriman; S J Zinreich; Patrick C Walsh
The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia.
The Prostate 1993;22(1):39-42.
1992: C P Tardif; Alan W Partin; Bahjat F Qaqish; Jonathan I Epstein; James L Mohler
Comparison of nuclear shape in aspirated and histologic specimens of prostatic carcinoma.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 1992;14(6):474-82.
1992: B R Lee; Alan W Partin; Jonathan I Epstein; D M Quinlan; John A Gosling; John P Gearhart
A quantitative histological analysis of the dilated ureter of childhood.
The Journal of urology 1992;148(5):1482-6.
1992: Jonathan I Epstein; Galina Pizov; Gary D Steinberg; H Ballentine Carter; R Pitcock; O A Armas; Alan W Partin; Patrick C Walsh
Correlation of prostate cancer nuclear deoxyribonucleic acid, size, shape and Gleason grade with pathological stage at radical prostatectomy.
The Journal of urology 1992;148(1):87-91.
1992: Alan W Partin; Gary D Steinberg; R V Pitcock; L Wu; Steven Piantadosi; Donald S Coffey; Jonathan I Epstein
Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer.
Cancer 1992;70(1):161-8.
1992: John P Gearhart; Alan W Partin; B Leventhal; J B Beckwith; Jonathan I Epstein
The use of nuclear morphometry to predict response to therapy in Wilms' tumor.
Cancer 1992;69(3):804-8.
1992: James L Mohler; Alan W Partin; Jonathan I Epstein; Robert L Becker; U V Mikel; Isabell A Sesterhenn; F K Mostofi; D F Gleason; Y Sharief; Donald S Coffey
Prediction of prognosis in untreated stage A2 prostatic carcinoma.
Cancer 1992;69(2):511-9.
1992: Alan W Partin; H Ballentine Carter; Jonathan I Epstein; Donald S Coffey
The biology of prostate cancer: new and future directions in predicting tumor behavior.
Monographs in pathology 1992;(34):198-218.
1992: Alan W Partin; J L Mohler; Donald S Coffey
Cell motility as an index of metastatic ability in prostate cancers: results with an animal model and with human cancer cells.
Cancer treatment and research 1992;59():121-30.
1991: O A Armas; Galina Pizov; R V Pitcock; Alan W Partin; Jonathan I Epstein
Nuclear morphology of prostatic carcinoma: comparison of computerized image analysis (CAS 200) versus video planimetry (DynaCELL).
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1991;4(6):763-7.
1991: Alan W Partin; J E Oesterling; Jonathan I Epstein; R Horton; Patrick C Walsh
Influence of age and endocrine factors on the volume of benign prostatic hyperplasia.
The Journal of urology 1991;145(2):405-9.
1990: Michael P Leonard; Alan W Partin; Jonathan I Epstein; RD Jeffs; John P Gearhart
Nuclear morphometry as a prognostic indicator for genitourinary rhabdomyosarcoma: a preliminary investigation.
The Journal of urology 1990;144(5):1222-6.
1990: H Ballentine Carter; Alan W Partin; Jonathan I Epstein; Daniel W Chan; Patrick C Walsh
The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.
The Journal of urology 1990;144(5):1167-70; discussion 1170-1.
1990: Alan W Partin; A C Walsh; Jonathan I Epstein; B G Leventhal; John P Gearhart
Nuclear morphometry as a predictor of response to therapy in Wilms tumor: a preliminary report.
The Journal of urology 1990;144(4):952-4.
1990: G F Murphy; Alan W Partin; Susan J Maygarden; James L Mohler
Nuclear shape analysis for assessment of prognosis in renal cell carcinoma.
The Journal of urology 1990;143(6):1103-7.
1990: Alan W Partin; H Ballentine Carter; Daniel W Chan; Jonathan I Epstein; J E Oesterling; R C Rock; J P Weber; Patrick C Walsh
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.
The Journal of urology 1990;143(4):747-52.
1990: W N Christensen; Alan W Partin; Patrick C Walsh; Jonathan I Epstein
Pathologic findings in clinical stage A2 prostate cancer. Relation of tumor volume, grade, and location to pathologic stage.
Cancer 1990;65(4):1021-7.
1990: William B Isaacs; John T Isaacs; Natasha Kyprianou; J K Burgers; Richard B Alexander; Alan W Partin; J L Mohler; Fray F Marshall; Donald S Coffey
New approaches to the evaluation of the metastatic ability of renal cancer and new approaches to chemotherapy.
European urology 1990;18 Suppl 2():33-5.
1989: H Ballentine Carter; Alan W Partin; Donald S Coffey
Prediction of metastatic potential in an animal model of prostate cancer: flow cytometric quantification of cell surface charge.
The Journal of urology 1989;142(5):1338-41.
1989: Alan W Partin; A C Walsh; R V Pitcock; James L Mohler; Jonathan I Epstein; Donald S Coffey
A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis.
The Journal of urology 1989;142(5):1254-8.
1989: W S Ward; Alan W Partin; Donald S Coffey
DNA loop domains in mammalian spermatozoa.
Chromosoma 1989;98(3):153-9.
1989: Kenneth J Pienta; Alan W Partin; Donald S Coffey
Cancer as a disease of DNA organization and dynamic cell structure.
Cancer research 1989;49(10):2525-32.
1989: J P Weber; J E Oesterling; C A Peters; Alan W Partin; Daniel W Chan; Patrick C Walsh
The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia.
The Journal of urology 1989;141(4):987-92.
1989: D M Quinlan; Randy J Nelson; Alan W Partin; Jacek L Mostwin; Patrick C Walsh
The rat as a model for the study of penile erection.
The Journal of urology 1989;141(3):656-61.
1989: Alan W Partin; J S Schoeniger; J L Mohler; Donald S Coffey
Fourier analysis of cell motility: correlation of motility with metastatic potential.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(4):1254-8.
1989: Alan W Partin; Jonathan I Epstein; Kathleen R Cho; A M Gittelsohn; Patrick C Walsh
Morphometric measurement of tumor volume and per cent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer.
The Journal of urology 1989;141(2):341-5.
1988: Alan W Partin; John T Isaacs; B Treiger; Donald S Coffey
Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene.
Cancer research 1988;48(21):6050-3.
1988: James L Mohler; Alan W Partin; John T Isaacs; Donald S Coffey
Metastatic potential prediction by a visual grading system of cell motility: prospective validation in the Dunning R-3327 prostatic adenocarcinoma model.
Cancer research 1988;48(15):4312-7.
1988: James L Mohler; Alan W Partin; W D Lohr; Donald S Coffey
Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. I. Testing of a digitization system.
The Journal of urology 1988;139(5):1080-4.
1988: James L Mohler; Alan W Partin; Jonathan I Epstein; W D Lohr; Donald S Coffey
Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. II. Standardization of methodology for histologic sections.
The Journal of urology 1988;139(5):1085-90.
1987: J L Mohler; Alan W Partin; Donald S Coffey
Prediction of metastatic potential by a new grading system of cell motility: validation in the Dunning R-3327 prostatic adenocarcinoma model.
The Journal of urology 1987;138(1):168-70.
1987: J L Mohler; Alan W Partin; Donald S Coffey
Correlation of prognosis to nuclear roundness and to flow cytometric light scatter.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 1987;9(2):156-64.
1987: J L Mohler; Alan W Partin; William B Isaacs; Donald S Coffey
Time lapse videomicroscopic identification of Dunning R-3327 adenocarcinoma and normal rat prostate cells.
The Journal of urology 1987;137(3):544-7.